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MAMMALIAN MULTIPOTENT NEURAL
STEM CELLS AND COMPOSITIONS,
METHODS OF PREPARATION AND
METHODS OF ADMINISTRATION THEREOF

2

several mammalian species, including, mice, rats, pigs and
humans. See, e.g., International Application, Publication
Nos. WO 93/01275, WO 94/09119, WO 94/10292, WO
94/16718 and Cattaneo et al., 1996, Mal. Brain Res. 42:
161-66. NSCs from the embryonic and adult rodent central
nervous system (CNS) have been isolated and further propaThis application is related to U.S. Provisional Patent Appligated in vitro in a variety of culture systems. See, e.g., Frolications, Ser. No. 60/348,473, filed Jan. 14, 2002, and Ser. No.
chsthal-Schoeller et al., 1999, NeuroReport 10: 345-351;
60/357,783, filed Feb. 19, 2002, and Ser. No. 60/376,257,
Doetsch et al., 1999, Cell 97: 703-716. NSCs from the human
filed Apr. 29, 2002, and Ser. No. 60/381,138, filed May 8,
2002, and Ser. No. 60/404,361, filed Aug. 19, 2002, and Ser. 10 fetal brain have been cultured using serum-free medium
supplemented with epidermal growth factor (EGF) and/or
No. 60/430,381, filed Dec. 2, 2002, the disclosures of each of
basic fibroblast growth factor (bFGF). See, e.g., Svendsen et
which are expressly incorporated by reference herein.
al., 1998, J. Neuroscience Methods 85: 141-152; Carpenter et
This invention was made with support from the U.S Goval., 1999, Experimental Neurology 158: 265-278. NSCs culermnent through the National Institutes of Health, grant no.
R03-AG19874. The govermnent has certain rights in this 15 tured utilizing these, serum-free, mitogen-supplemented
methods generally form substantially undifferentiated, clusinvention.
tered aggregates. Upon removal of the mitogen( s) and provision of a substrate, the stem cells differentiate into neurons,
BACKGROUND OF THE INVENTION
astrocytes and oligodendrocytes.
While the synaptic connections involved in neural circuits
20
1. Field of the Invention
are continuously altered throughout the life of the individual,
This invention relates to novel mammalian multipotent
due to synaptic plasticity and cell death, neurogenesis, the
neural stem cells (MNSCs), compositions thereof, and methgeneration of new neurons, was thought to be complete early
ods of preparing and administering such cells. In one aspect,
in the postnatal period. The discovery ofNSCs in adult brain
the invention relates to methods of making one or a plurality
of mammalian multipotent stem cells that can form a cluster. 25 (see, e.g., Alvarez-Buylla et al., 1997, J. Neurobiology 33:
585-601; Gould et al., 1999, Science 286: 548-552) has
In another aspect, the invention relates to cells prepared
brought significant changes in the theory on neurogenesis as
according to the methods of the invention. In another aspect,
the presence ofMNSCs in the adult brain suggests that regenthe invention relates to pharmaceutical compositions comeration of neurons can occur throughout life. Nevertheless,
prising one or a plurality of mammalian multipotent stem
cells that can form a cluster of the invention. In another 30 age, physical and biological trauma or neurodegenerative
disease-associated loss of brain function, herein referred to as
aspect, the invention relates to cellular preparations for cell or
a "neurological deficit," can far outweigh any potential restortissue regeneration comprising one or a plurality of mammaative effects due to endogenous neurogenesis. As a result,
lian multipotent stem cells that can form a cluster of the
transplantation ofNSCs is a potentially valuable treatment for
invention. In another aspect, the invention relates to a method
for regenerating cells or tissue comprising administering one 35 those suffering from the loss of, or loss of appropriate, brain
function due to age, physical and biological trauma or neuor a plurality of mammalian multi potent stem cells that can
rodegenerative disease; a neurological deficit.
form a cluster of the invention to an animal in need thereof. In
Due to the advancing average age of the population, and
another aspect, the invention relates to a method for treating
concomitantly increased incidence of neurological deficit
an animal or human having a neurological or corporal deficit
comprising the step of administering one or a plurality of 40 that: accompanies advancing age, treatment of neurodegenerative diseases has become a major concern. Such diseases,
mammalian multipotent stem cells that can form a cluster of
including Alzheimer's disease, Huntington's chorea and Parthe invention or terminally differentiated cells produced
kinson's disease, have been linked to neural degeneration at
according to the invention to an animal, including human, in
specific locations in the brain, leading to the inability of the
need thereof. In another aspect, the invention relates to a
method of making and using a terminally differentiated cell 45 brain region to synthesize and releases neurotransmitters that
are vital to neural signaling.
utilizing one or a plurality of mammalian multipotent stem
Neurodegeneration also encompasses many conditions
cells that can form a cluster of the invention.
and diseases, age-related or not, that result in neural loss.
2. Background of the Related Art
These conditions include CNS trauma, such as stroke and
Stem cells are often defined as self-renewing and multipotent, with the ability to generate diverse types of differentiated 50 epilepsy, as well as diseases that result in neural loss, including amyotrophic lateral sclerosis and cerebral palsy.
cells. As such, they show promise in the treatment of neuroDegeneration in a brain region known as the basal ganglia
logical and corporal deficits, or any loss or diminishment of
can
lead to diseases with varied and different cognitive and
tissue function due to age, disease, trauma or other factor.
motor symptoms, depending on the exact location of the
However, such treatments have faced significant hurdles that
55 lesion. The basal ganglia consists of many separate regions,
have yet to be substantially overcome.
including the striatum (which consists of the caudate and
NSCs and Neurological Deficits
putamen), the globus pallidus, the substantia nigra, substantia
Because one important focus of stem cell replacement
innominata, ventral pallidum, nucleus basalis of Meynert,
ventral tegmental area and the subthalamic nucleus.
therapies has been neurological disorders, neural stem cells,
and particularly fetal neural stem cells, have been a major 60
Degeneration in the basal ganglia can lead to motor deficits. For example, Huntington's chorea is associated with
research target. During development of the central nervous
degeneration of neurons in the striatum, which leads to involsystem (CNS), multipotent neural stem cells (MNSCs), also
known as multipotent precursor cells (MPCs) or neural stem
untary jerking movements. Degeneration of a small region
cells (NSCs), proliferate, giving rise to transiently dividing
called the subthalamic nucleus is associated with violent
progenitor cells that eventually differentiate into the cell 65 flinging movements of the extremities in a condition called
ballismus, while degeneration in the putamen and globus
types that compose the adult brain, including neurons, astropallidus are associated with a condition of slow writhing
cytes and oligodendrocytes. NSCs have been isolated from

US 7,618,621 B2
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movements or athetosis. In Parkinson's disease, degeneration
is seen in another area of the basal ganglia, the substantia
nigra par compacta. This area normally sends dopaminergicconnections to the dorsal striatum, which are is? important in
regulating movement. Therapy for Parkinson's disease has
centered upon restoring dopaminergic activity to this circuit.
Alzheimer's disease patients exhibit a profound cellular
degeneration of the forebrain and cerebral cortex. Further, a
localized area of the basal ganglia, the nucleus basalis of
Meynert, appears to be selectively degenerated. This nucleus
normally sends cholinergic projections to the cerebral cortex
that are thought to participate in cognitive functions including
memory.
The objective of most CNS therapies is to regain the particular chemical function or enzymatic activity lost due to
cellular degeneration. Administration of pharmaceutical
compositions has been the main treatment for CNS dysfunction. Unfortunately, this type of treatment has many complications, including the limited ability to transport drugs across
the blood-brain barrier, and drug-tolerance acquired by
patients to whom these drugs are administered for long-periods.
Transplantation of multipotent stem cells may avert the
need not only for constant drug administration, but also for
complicated drug delivery systems necessitated by the bloodbrain barrier. In practice, however, significant limitations
have been found in this technique as well. First, cells used for
transplantation that carry cell surface molecules of a differentiated cell from a donor can induce an immune reaction in
the recipient, a problem that is exacerbated by the physical
damage caused by injection of cells directly into the affected
area of the brain. In addition, the neural stem cells must be at
a developmental stage where they are able to form normal
neural connections with neighboring cells. For these reasons,
initial studies on neurotransplantation centered on the use of
fetal cells.
Mammalian fetal brain tissue has proven to have reasonable survival characteristics upon immediate transplantation.
Increased survival capability of fetal neurons is thought to be
due to the reduced susceptibility of fetal neurons to anoxia
compared to adult neurons. An additional factor favoring
survival of fetal cells is the lack of cell surface markers on
fetal cells, whose presence may lead to rejection of grafted
tissue from adults. However, although the brain is considered
an immunologically privileged site, some rejection of even
fetal tissue can occur. Therefore, the ability to use heterologous fetal tissue is limited by tissue rejection and the need for
immunosuppressant drugs.
The use of large quantities of aborted fetal tissue presents
other difficulties as well. Fetal CNS tissue is composed of
more than one cell type, and thus is not a well-defined tissue
source. In addition, there are doubts as to whether an adequate
and constant supply of fetal tissue would be available for
transplantation. For example, in the treatment of MPTP-induced Parkinsonism, tissue from as many as 6 to 8 fetuses can
be required for successful implantation into the brain of a
single patient. There is also the added problem of the potential
for contamination during fetal tissue preparation. Since these
tissue may already be infected with a bacteria or virus, expensive diagnostic testing is required for each fetus used. Even
comprehensive diagnostic testing might not uncover all
infected tissue. For example, there can be no guarantee that a
sample is HIV-free, because antibodies, to the virus are generally not present until several weeks after infection.
In addition to fetal tissue, there are other potential sources
of tissue for neurotransplantation, including cell lines and
genetically engineered cell types, but both sources present

problems. Cell lines are immortalized cells that are derived,
inter alia, by transformation of normal cells with an oncogene
or by the culturing of cells in vitro with altered growth characteristics. Moreover, adverse immune response potential,
the use of retroviruses to immortalize cells, the potential for
the reversion of these cells to an amitotic state, and the lack of
response by these cells to normal growth-inhibiting signals
make such cell lines sub-optimal for widespread use.
Another approach to neurotransplantation involves the use
of genetically engineered cell types or gene therapy. However, there still exists a risk of inducing an immune reaction
with these cells. In addition, retrovirus mediated transfer may
result in other cellular abnormalities. Also, cell lines produced by retrovirus-mediated gene transfer have been shown
to gradually inactivate their transferred genes following
transplantation and further may also not achieve normal neural connections with the host tissue.
While currently available transplantation approaches represent an improvement over other available treatments for
neurological disorders, they suffer from significant drawbacks. The inability in the prior art of the transplant to fully
integrate into the host tissue, and the lack of availability of
suitable cells in unlimited amounts from a reliable source for
grafting are significant limitations of neurotransplantation.
Studies utilizing intra-tissue injection of dissociated and partially differentiated NS Cs have shown little promise (see, e.g.,
Benninger et al., 2000, Brain Pathol. 10: 330-341; Blakemore
et al. 2000, Cell Transplant 9: 289-294; Rosser et al., 2000,
Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000, Mal. Cell
Neurosci. 16: 1-13). The results have generally been poor
because, among many considerations, the dissociation of
clusters ofNSCs is known to cause immediate senescence of
NSCs and increase the vulnerability ofNSCs in culture. See,
e.g., Svendsen et al., 1998,J. Neurosci. Methods 85: 141-152.
Further, regardless of adverse immune responses due to foreign tissue being introduced into the brain, the trauma caused
by the physical introduction of cells directly into the damaged
area can induce the recruitment of immune cells by the host
that can eliminate the transplanted cells. Thus, significant
problems with the use of NSCs to ameliorate neurological
deficits remain.
As described herein, neurological deficits also include
non-brain tissues such as, for example, the eye and spinal
cord. In addition, corporal deficits are a target for amelioration utilizing multipotent stem cells. A "corporal deficit" is a
disorder caused by a wide variety of diseases and injuries,
resulting in trauma, malfunction, degeneration or loss of
muscle such as, for example, cardiac muscle due to myocardial infarction. Other examples include malfunction, degeneration or loss of other cells and tissues apart from those
discussed in the neurological deficit section above such as, for
example, internal organs. For example, liver function can be
adversely affected by, among other things, disease (e.g., cirrhosis or hepatitis), trauma or age. The problems described
above in using NSCs to remedy neurological deficits of the
brain also apply to neurological deficits in other tissues, such
as the eye, and corporal deficits.
There exists a need in the art for improved methods for
introducing multipotent neural stem cells to diseased, aged or
damaged tissue such that the cells properly migrate and differentiate and a neurological or corporal deficit is improved or
remedied as a result. In addition, there remains a need for
methods of use or administration of the multipotent stem cells
of the invention, or pharmaceutical preparations thereof, to
the affected, damaged or degenerated tissue, wherein the stem
cells can differentiate in a manner appropriate for the host
tissue and enable the replacement of damaged cells, repair of
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damages tissue and, optionally, amelioration of functional
loss. There also remains a need in the art for a reliable source
of unlimited numbers of cells for transplantation, particularly
cells that are specifically adapted for and capable of proliferation, migration, and differentiation in mannnalian brain or
other tissues when introduced thereto. Furthermore, there
exists a need in the art for methods for repairing damaged
neural and other tissue in as non-invasive a fashion as possible, especially by inducing multipotent stem cells to proliferate and differentiate in vivo into, for example, neurons,
astrocytes, and oligodendrocytes in the brain or, for example,
rod or cone photoreceptor cells, horizontal cells, bipolar cells,
amacrine cells, ganglion cells, Muller cells, and nerve cells in
the eye. Further, there remains a need for a method of making
a terminally differentiated cell from and a method of administering the one or plurality of mammalian multi potent stem
cells that can form a cluster produced according to the methods of the invention.

astrocytes. As provided herein, the methods of the invention
provide one or a plurality of mammalian multipotent stem
cells that can form a cluster.
In a second aspect, the invention provides one or a plurality
of mammalian multipotent stem cells that can form a cluster
that preferably comprise less than about 50 percent, more
preferably less than about 25 percent, even more preferably
less than about 10 percent, even more preferably less than
about 5 percent, and even more preferably less than about 1
percent differentiated neural stem cells. In certain embodiments, the invention in this aspect provides a preparation for
cell or tissue regeneration comprising, as an active ingredient,
one or a plurality of mammalian multipotent stem cells that
can form a cluster produced according to the methods of the
invention. In other related embodiments, the invention provides terminally differentiated cells produced from the one or
plurality of mannnalian multipotent stem cells that can form
a cluster.
In yet further aspects of the invention are provided pharmaceutical compositions comprising said one or plurality of
mammalian multipotent stem cells that can form a cluster
prepared according to the methods of the invention and a
pharmaceutically-acceptable carrier or excipient. The invention provides such pharmaceutical compositions comprising
said one or plurality of mammalian multipotent stem cells
that can form a cluster that are tissue stem cells for use in cell
or tissue regeneration or for correcting a disease or disorder in
an tissue or animal in need thereof. In certain embodiments,
the one or plurality of mammalian multipotent neural stem
cells of the invention are neural stem cells for use in correcting, treating or ameliorating a neurological disease or disorder in an animal in need thereof. In certain embodiments, the
invention in this aspect provides a preparation for cell or
tissue regeneration comprising, as an active ingredient, one or
a plurality of mammalian multipotent stem cells; that can
form a cluster produced according to the methods of the
invention.
Thus, the invention also provides methods for using the
pharmaceutical compositions provided herein to treat an animal in need thereof by administering the one or plurality of
mammalian multipotent neural stem cells of the invention
thereto. Preferably, the animal has a corporal or neurological
deficit that can be treated or ameliorated by administration of
the one or plurality of mammalian multipotent neural stem
cells of the invention, such as a deficit caused by a neurodegenerative disease, a traumatic injury, a neurotoxic injury,
ischemia, a developmental disorder, a disorder affecting
vision, an injury or disease of the spinal cord, a demyelinating
disease, an autoimmune disease, an infection, an inflammatory disease, or corporal disease, disorder, injury, trauma,
malfunction, degeneration or loss. In preferred embodiments,
the one or plurality of mammalian multipotent neural stem
cells is capable of migrating to an area of tissue damage,
differentiate in a tissue-specific marmer and function in a
manner that reduces the neurological or corporal deficit. As
provided by the methods of the invention herein, the cells are
administered by injecting the one or plurality, of mannnalian
multipotent neural stem cells with a syringe, inserting the one
or plurality of mammalian multipotent neural stem cells with
a catheter or surgically implanting the mammalian neural
stem cells. In certain embodiments, the one or plurality of
mammalian multipotent neural stem cells are injected with a
syringe into a body cavity that is fluidly-connected to the area
of neurological or corporal deficit. In certain preferred
embodiments, the body cavity is a brain ventricle. In other
embodiments, the one or plurality of mammalian multi potent
neural stem cells are inserted with a catheter into a body
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SUMMARY OF THE INVENTION
This invention provides methods for producing multipotent stem cells, particularly neural stem cells, and cells produced by those methods. In particular, the invention provides
reagents and methods for efficiently producing neural stem
cells that can be reintroduced into an animal in need thereof to
alleviate neurological or corporal disorders.
In a first aspect, the invention provides methods for preparing one or a plurality of mammalianmultipotent stem cells
that can form a cluster comprising the steps ofisolating mammalian neural stem cells (MNSCs) derived from mannnalian
neural tissue containing at least one neural stem cell; culturing said cells in a cell culture media under conditions that
permit proliferation of the neural stem cells in vitro;; and
harvesting the cluster of mammalian stem cells produced in
above, wherein said one or plurality of mammalian multipotent stem cells that can form a cluster is adapted for proliferation, migration and differentiation in mammalian tissue
when introduced thereto. In certain embodiments, the methods comprise the additional steps of culturing said cells in a
cell culture media comprising an effective amount of substituted deoxynucleotide or deosynucleoside compound for an
effective period. In certain embodiments, the inventive methods further comprise the step of contacting a MNSC with
substituted deoxynucleotide of deoxynucleoside compound
in an uncoated flask or a flask that has been treated to repel the
cells. In further embodiments, the MNSC cell is further contacted with a growth factor such as fibroblast growth factor,
epidermal growth factor or a combination thereof. Alternatively, the MNSCs are contacted additionally with heparin.
Exemplary substituted deoxynucleotide or deoxynucleoside compounds as provided by the invention include but are
not limited to halogen-substituted (halo-substituted) deoxynucleotides or deoxynucleosides, such as, for example, bromodeokyunridine, iododeoxyuridine, bromodeoxyguanosine, iododeoxycytosine as well as alkyl-substituted
species such as, for example, methyldeoxythymidine. A most
preferred species is bromodeoxyuridine (BrdU). In certain
embodiments, the mammalian neural stem cells are obtained
from any tissue containing stem cells including but not limited to zygote, blastocyst, embryo, fetus, infant juvenile or
adult, and optionally, a human species of any of the preceding
embodiments, whether naturally occurring or engineered.
Said cells in some embodiments comprise neural-lineage
cells such as neural stem cells, neurons, oligodendrocytes and
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cavity that is fluidly-connected to the area of neurological or
corporal deficit. In certain preferred embodiments, the body
cavity is a brain ventricle. In still further additional embodiments, the one or plurality of marmnalian multi potent neural
stem cells are surgically implanted into a body cavity that is
fluidly-connected to the area of neurological or corporal deficit. In certain preferred embodiments, the body cavity is a
brain ventricle. The one or plurality of mammalian multi potent neural stem cells can also alternatively be inserted using
a syringe or catheter or surgically implanted directly at the
site of the neurological or corporal deficit or systemically
(e.g., intravenously). In certain related embodiments, the
invention provides a method for treating a patient having a
neurological; deficit or corporal deficit with terminally differentiated cells of the invention, comprising the step of
administering said terminally differentiated cells to an animal
having a neurological deficit or corporal deficit.

Specific embodiments of the present invention will become
evident from the following more detailed description of certain preferred embodiments and the claims.

In still further aspects, the invention provides a method of
making a retinal cell, the method comprising contacting a
neural stem cell; before or during differentiation with an
effective amount of growth factor selected from the group
consisting ofTGF-b3, CNTF and IGF-1, or a combination of
two or more said group, for an effective period, wherein the
growth factor-contacted neural stem cells become capable of
differentiating into retinal cells. The invention also provides
the cells produced according to these methods, which can be
used to treat a patient, animal or human, having a neurological
deficit, where the retinal cell produced according to these
methods, when administered, are capable of migrating to an
area of tissue damage, differentiating ina tissue-specific manner and functioning in a manner that reduces the neurological
deficit. In preferred embodiments, the retinal cells produced
according to these methods can be used in treating a neurological deficit relating to tissues of the eye.
Thus, the present invention provides what is needed in the
art: one or a plurality of novel marmnalian multipotent neural
stem cells (MNSCs) that can form a cluster, compositions
thereof, and methods of preparing and administering the cells
to diseased, aged or damaged tissue, wherein the cells properly migrate and differentiate and a neurological or corporal
deficit is improved or remedied as a result. More specifically,
the invention provides methods of making one or a plurality
of mammalian multipotent neural stem cells that can form a
cluster; cells prepared according to the methods of the invention; pharmaceutical compositions comprising one or a plurality of mammalian multipotent neural stem cells that can
form a cluster of the invention; cellular preparations for cell or
tissue regeneration comprising one or a plurality of mammalian multipotent neural stem cells of the invention; a method
for regenerating cells or tissue comprising administering one
or a plurality of the marmnalian multipotent neural stem cells
of the invention; a method for treating a patient having a
neurological or corporal deficit comprising administering
one or a plurality of mammalian multipotent neural stem cells
of the invention; a method of administering one or a plurality
of mammalian multipotent neural stem cells that can form a
cluster produced according to the method of the invention; a
method of making a terminally differentiated cell utilizing
one or a plurality of mammalian multipotent neural stem cells
of the invention; and methods of making retinal cells from
neural stem cells, methods of use thereof and the cells produced according to those methods.

BRIEF DESCRIPTION OF THE DRAWINGS
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FIG. 1. shows a phase contrast photomicrograph of a floating, aggregated cluster of cells, characteristic of certain
embodiments of the cells of the invention.
FIG. 2 shows the effect ofNSC transplantation on memory
score in the Morris water maze test. (a) Individual memory
score before and after transplantation shows improvement in
the majority of the animals. Blue: Aged memory impaired
animals, Green: Aged memory unimpaired animals, Red:
Matured animals. (b) Mean of memory score in each animal
group before (narrow striped bar) and after (black bar)
MNSCs transplantation shows a significant improvement in
aged memory impaired and young animals. The animals that
received vehicle injection do not show significant difference
in memory score between before (wide striped bar) and after
(hatched) the injection.
FIG. 3 shows typical fluorescent immunohistochemical
photomicrographs of aged rat brain 30 days after NSCs transplantation. bIII-tubulin and GFAP immunoreactivity were
used as markers forneuronandglia, respectively. (a) MNSCs
of the invention migrated into the cortex and differentiated
into neurons as indicated by the bIII-tubulin positive cells
(green), which have morphologies typical of pyramidal cells
in layer IV and V, of the parietal cortex. Apical dendrites were
pointed towards to the edge of the cortex. Since the NSCs
were pre-treated with BrdU, the transplanted cells have BrdU
positive nuclei (red). Contrarily, the host cell's nuclei are
counter stained with DAPI (blue). Many cells having BrdU
positive nuclei are observed with bIII-tubulin immunoreactivity in layer II and without bIII-tubulin immunoreactivity in
layer III. (b, c) Higher magnification of the parietal cortex in
cortex layer IV: All the bIII-tubulin immunoreactive (green)
positive cells show BrdU (red) positive nuclei while many
other host cell's nuclei are stained with only DAPI (blue).
NSCs tend to have larger nuclei than host cells. (d) NSCs
migrated into the hippocampus and differentiated into bIIItubulin positive cells. (green), in CAI pyramidal cell layer.
These bIII-tubuln positive cells have BrdU positive nuclei
(red), indicating that these cells originated from transplanted
cells. In contrast, host cell nuclei counter stained with DAPI
(blue) are not bIII-tubulin positive. (e) In the dentate gyrus
many fibers were bIII-tubulin positive in addition to the bIIItubulin positive cells (green) and GFAP positive sells (red),
(f) bIII-tubulin positive cells (green) and GFAP positive cells
(red) were found in layer IV and layer III, respectively. Such
a layer of astrocytes were not observed in normal rats without
NSC transplantation.
FIG. 4 shows co-localization of bIII-tubulin (a neural
marker) and BrdU immunoreactivity in the same cells. (a-c)
Three different planes of the same microscopic view. The
bIII-tubulin positive cells (green) show BrdU positive nuclei
(red) indicating that these cells are derived from transplanted
NSCs.
FIG. 5 shows the immunocytochemistry of HNSCs with
bIII-tubulin (green, neuron), GFAP (red, astrocytes) and
DAPI (blue, nuclei) differentiated in non-serum media.
FIG. 6 shows spontaneous differentiation of NSCs in
serum-free basal media. Mixed populations of differentiating
cells are coronally migrating out from a cluster of cells
located on the top of the picture.
FIGS. 7(I) and (II) shows differentiation of human NSCs
into retinal cells in vitro. All nuclei were counter stained by
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DAPI (blue). (I.a) Typical immunocytochemistry of NSCs
differentiated in basal media. Double-immunofluorescence
staining was performed using GFAP (red) and bIII-tubulin
(green) markers for astrocytes and neural cells, respectively.
(I.b) Typical immunocytochemistry ofNSCs differentiated in
basal media after 5 days differentiation. Cells were doubleimmunofluorescence stained with GFAP (red) and opsin
(green) markers for astrocytes and photoreceptor cells,
respectively. Opsin immunoreactivity was not detected in
NSCs spontaneously differentiated in basal media condition
without any additional factors. (I.c) Typical immunocytochemistry ofNSCs differentiated in basal media under the
influence of transforming growth factor-beta3 (TGF-b3, 100
ng/ml). Double-immunofluorescence staining with GFAP
(red) and opsin (green) markers for astrocytes and retinal
cells, respectively. (I.d) Typical immunocytochemistry of
NSCs differentiated in basal media in the absence ofTGF-b3
after 3 days treatment with 100 ng/ml of TGF-b3. Doubleimmunofluorescence staining with GFAP (red) and opsin
(green) markers for astrocytes and retinal-cells, respectively.
The cells of FIG. 7 (II) were grown in seruni-free differentiation conditions in the presence of 20 ng/ml of IGF-1 (II.a),
100 ng/ml ofTGF-b3 (II.b ), 10 ng/ml ofCNTF, or without the
preceding factors (control; II.d). Double immunofluorescence staining with GFAP (red), opsin (green), markers for
astrocytes and retinal cells, respectively. The blue signal represents counter staining for nuclei by DAPI. The NSCs can
differentiate into retinal cells through the action of the growth
factors in vitro.
FIGS. 8 (I) and (II) shows differentiation of NSCs into
retinal cells in vivo. All nuclei were counterstained by DAPI
(blue). (a) Typical immunocytochemistry of a control retinal
section without any lesion or NSC transplantation (xlOO).
The section was double-immunofluorescence stained with
BrdU (red) and opsin (green) markers for donor cells and
photoreceptor cells, respectively. (b) Typical immunocytochemistry of retinal sections 4 weeks after a lesion and NSC
transplantation (xl 00). The section was double-immunofluorescence stained with BrdU(red) and opsin (green) markers
for donor cells and photoreceptor cells, respectively. NSCs
migrated into damaged area of the retinal tissue. A higher
magnification (c, x400) shows that these migrating NSCs also
show cytosolic expression of op sin. (d) Typical in situ hybridization histochemistry for human opsin gene expression
using human-specific opsin sequence riboprobes in a section
next to the section immunostained in (c ). Human op sin gene
expression is visualized in green fluorescent stain. FIG. 8 (II)
immunohistochemistry ofNSCs treated with certain growth
factors were able to differentiate to retinal cells upon transplantation to the eye. NSCs grown in basal media differentiated to op sin-expressing cells in vivo after exposure to IGF-1,
TGF-b3 or CNTF for four days. Cells were treated with 20
ng/ml ofIGF-1, 100 ng/ml ofTGF-b3, or 10 ng/ml ofCNTF
prior to transplantation into rat eye. Double immunofluorescence staining with GFAP (red), opsin (green), markers for
astrocytes and retinal cells, respectively. The blue signal represents counter staining for nuclei by DAPI. The transplanted
NSCs can differentiate into retinal cells through the action of
the growth factors.
FIG. 9 shows increased GFAP imrmunoreactivity in the
NBM 4 weeks after saporin lesion. Green: GFAP; Blue:
DAPI.
FIG. 10 shows choline acetyltransferase (ChAT) immunoreactivity in BrdU positive cells in the lesion site indicating
replacement of lesioned cells by the transplanted cells of the
invention (a-c; Green: ChAT; Red: BrdU; Blue: DAPI) and

ChAT immunoreactivity in human nuclei positive cells in the
lesion site (d; Green: CHAT; Red: human nuclei; Blue:
DAPI).
FIG. 11 shows human nuclei immunoreactivity-positive
cells that were observed in the lesion area. Red: human
nuclei; Blue: DAPI.
FIG. 12 shows GFAP and human nuclei immunoreactivity
in the lesion site. Green: GFAP; Red: human nuclei; Blue:
DAPI.
10
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This invention provides one or a plurality of manimalian
multipotent neural stem cells that can form a cluster and are
specially adapted for proliferation, migration and differentiation in mammalian tissue when introduced thereto. Such cells
are capable of differentiating in a tissue specific manner,
particularly neural stem cells capable of differentiating inter
alia, in brain tissues and that can be administered to an animal
in need thereof.
As disclosed in further detail herein, the inventive: methods provide for culturing mammalian neural stem cells
obtained, inter alia, from somatic tissue sources, and producing multipotent neural stem cells specially adapted for proliferation, migration and differentiation therefrom. In one
aspect, this effect is achieved by culturing mammalian neural
stem cells in the presence of a substituted deoxynucleotide or
deoxynucleoside compound. Exemplary substituted deoxynucleotide or deoxynucleoside compounds include but are
not limited to halogen-substituted (halo-substituted) deoxynucleotide or deoxynucleoside species such as, for example,
bromodeoxyuridine, iododeoxyuridine, bromodeoxyguanosine, iododeoxycytosine as well as alkyl-substituted species such as, for example, methyldeoxythymidine. A most
preferred species is bromodeoxyuridine (BrdU). BrdU is a
thymidine analog that was originally, produced for chemotherapy. It is known to regulate gene expression and cellular
differentiation of some cell types. Since BrdU; and other
substituted deoxynucleotide or deoxynucleoside compounds
are incorporated into the nuclei of proliferating cells and are
easy to detect by immunostaining, it has been used for detecting proliferating cells, such as stem cells; however, its biological effects on stem cells have not been appreciated, understood or disclosed in the art.
The invention relates to methods of making manimalian
multipotent neural stem cells specially adapted for proliferation, migration and differentiation from manimalian neural
stem cells (NSCs ), as well as methods of treatment and use of
the specially adapted MNSCs, and the specially adapted
MNSCs themselves. Thus, the present invention provides a
means to treat neurological and corporal deficits.
As used herein, the terms "multipotent neural stem cells
(MNSCs),", "neural stem cells. (NSCs)," "multipotent precursor cells (MPCs)" and "neural progenitor cells (NPCs)"
refer to undifferentiated, multipotent cells of the CNS. Such
terms are commonly used in the scientific literature. MNSCs
can differentiate into tissue-specific cell types, for example
astrocytes, oligodendrocytes, and neurons when transplanted
in the brain. MNSCs of the invention are distinguished from
natural MNSCs by their adaptation for proliferation, migration and differentiation in mammalian host tissue when introduced thereto.
As used herein, the term "cluster" refers to a group of two
or more cells. A cluster can take any shape but such groups of
non-terminally differentiated multipotent cells often assume
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a generally spherical shape. The clusters can comprise the
progeny of a single multipotent neural stem cell or small
cluster of primary cells.
As used herein, the terms "effective amount" and "therapeutically effective amount" each refer to the amount of
reagent used to support the desired activity. In the case of the
cells prepared and delivered according to the invention, an
effective amount is an amount necessary to support an
observable level of one or more biological activities ofMNSC
as set forth herein. Regarding substituted deoxynucleotide or
deoxynucleoside compounds, an effective amount can be
between about 10 nanomolar and 100 micromolar, or more
preferably between about 2 and 50 micromolar, or even more
preferably about 10 micromolar. Regarding growth factors,
an effective amount can be between about 1 ng/ml to 1 ug/ml,
or more preferably between about 5 ng/ml to 500 ng/ml, or
even more preferably between about 10 ng/ml to 100 ng/ml,
or even more preferably about 50 ng/ml.
An "effective period" as used herein refers to the time
period necessary for the reagents and cells of the invention to
accomplish their specified activities. For example, less developmentally potent cells can be contacted with a substituted
deoxynucleotide or deoxynucleoside compound for an effective period to make them more developmentally potent. An
effective period for contact with a substituted deoxynucleotide or deoxynucleoside compound, as referred to herein,
can be between 1 to 10 days, or more preferably between
about 1 to 5 days, or even more preferably between about 2 to
3 days. An effective period for growth factor contact, as with
the substituted deoxynucleotide or deoxynucleoside compounds, can be between about 1 to 10 days, or more preferably between about 1 to 7 days, or even more preferably
between about 2 to 5 days.
The term "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refers to one or
more formulation materials suitable for accomplishing or
enhancing the successful delivery of the pharmaceutical composition of the specially adapted MNSCs prepared and delivered according to the invention.
As used herein, "ameliorating the effects caused by age,
physical and biological trauma and degenerative disease" and
the like refers to the diminution of the detrimental effects of
damaged or degenerated tissue due to the use or administration of an effective amount of the specially adapted MNSCs
of the invention, or pharmaceutical preparations thereof, to
the affected, damaged or degenerated tissue, wherein the
neural stem cells can differentiate in a manner appropriate for
the host tissue and enable the replacement of damaged cells,
repair of damages tissue and reduction of structural or functional loss. For example, the neurological effects of events,
diseases or processes that result in the loss of some degree of
brain function or proper brain function. Such amelioration is
affected through the administration to the animal of an effective amount of the specially adapted MNSCs of the invention
or pharmaceutical compositions thereof.
The invention also provides pharmaceutical compositions
of the MNSCs of the invention and methods of delivery into
the brain and other tissues thereof. The invention also provides methods of abating or remedying the effects of brain or
other tissue disease or dysfunction caused by the loss of, or
loss of appropriate, brain or other tissue function due to age,
physical or biological trauma or neurodegenerative disease.
The invention provides specially adapted MNSCs capable
of differentiating in a tissue specific manner, and the MNSCs
can take and be administered in the form of clusters. Cells can
be obtained in many ways and from many tissues, for
example, from donor tissue by dissociation of individual cells

from the connecting extracellular matrix of the tissue or from
commercial sources of NSCs (e.g., Bio Whittaker, Walkersville, Md., CC-2599). Tissue from brain is removed using,
sterile procedures, and the cells are dissociated using any
method known in the art including treatment with enzymes
such as trypsin, collagenase and the like, or by using physical
methods of dissociation such as mincing or treatment with a
blunt instrument. Dissociation of neural cells can be carried
out in tissue culture medium; the medium for dissociation of
juvenile and adult cells is low calcium artificial cerebral spinal fluid (aCSF) having a formula as aCSF (124 mM NaCl, 5
mM KC!, 1.3 mM MgCl 2 , 2 mM CaCl 2 , 26 mM NaHC0 3 ,
and 10 mM D-glucose) except that MgCl 2 is present at a
concentration of3.2 mM and CaCl 2 at a concentration of0.1
mM. Dissociated cells are centrifuged at low speed, between
200 and 2000 rpm, usually between 400 and 800 rpm, the
suspension medium is aspirated, and the cells are then resuspended in culture medium suspension cultures are preferred if
large numbers of undifferentiated neural stem cell progeny
are desired. Cell suspensions are seeded in any receptacle
capable of sustaining cells, preferably uncoated flask or a
flask that has been treated to repel the cells, culture plates or
roller bottles that inhibit contact-dependent stem cell differentiation.
Growth of NSCs under the above culture conditions
induces or permits these cells to form undifferentiated clusters (shown in FIG. 1). These clusters are: optimally grown at
a density of approximately 50 spheres per T7 5 flask in 20 mL
of the growth medium consisting of, for example, DMEM/
HAMS F12 (at about 3:1; Gibco, BRL, Burlington, ON),
supplemented with an antibiotic-antimycotic mixture (1: 100,
penicillin G, streptomycin sulfate, amphotericin B; Gibco );),
B27 (1:50, GIBCO), humanrecombinantFGF-2 andEGF (20
ng/ml each, R&D Systems, Minneapolis, Minn.) and heparin
(5 µg/mL, Sigma, St. Louis, Mo.). The cultures are kept in a
C0 2 incubator (about 5% C0 2 ) at 3 7° C. To facilitate optimal
growth conditions, any clusters of two or more cells are
sectioned into quarters approximately every 14 days and fed
by replacing 50% of the medium approximately every 4-5
days. These conditions permit rapid and continual growth of
NSCs that can be expanded indefinitely while retaining: their
multipotent character. As with most eukaryotic cells, conditions for culturing should be as close as possible to physiological conditions. The pH of the culture medium should be
close to physiological pH, preferably between pH 6-8, more
preferably between about pH 7 to 7 .8, with pH 7.4 being most
preferred. Physiological temperatures range between about
30° C. to 40° C. Cells are preferably cultured at temperatures
between about 32° C. to about 38° C., land more preferably
between about 35° C. to about 37° C. In the case of neural
stem cells (NSCs), after more than three years of serum-free
propagation, NSCs prepared and maintained as disclosed
herein continue to exhibit multipotent character. If in vitro
differentiation is desired, the cells can be replated in culture
dishes in, for example, serum-free basal medium Eagle
(BME), which contains Earle's salt and L-glutamine. The
cells can be cultured for about 5 days in the absence ofFGF-2,
EGF or other extrinsic differentiation factors. When induced
to differentiate in this way, these cultured NSCs exhibit characteristic morphollogies of neurons or astrocytes when
immunohistochemically stained with b-III tubulin (a neural
cell marker) or glial fibrillary acidic protein (GFAP, an astrocyte marker).
As disclosed above, the stem cell culture medium as used in
the invention is preferably supplemented with at least one
proliferation-inducing growth factor. A growth factor, as
defined herein, refers to a protein, peptide or other molecule
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having a growth, proliferative, or trophic effect on the specially adapted MNSCs and MNSC progeny of the invention.
Growth factors that are used for inducing proliferation
include any trophic factor that allows NSCs to proliferate,
including any molecule that binds to a receptor on the surface
of the cell to exert a trophic, or growth-inducing effect on the
cell. Exemplary proliferation-inducing growth factors
include epidermal growth factor (EGF), insulin-like growth
factor-I IGF-1), ciliary neurotrophic factor (CNTF), amphiregulin, acidic fibroblast, growth factor (AFGF or FGF-1);
basic fibroblast growth factor (bFGF or FGF-2), transforming
growth factor alpha (TGFa), and combinations thereof. Preferred proliferation-inducing growth factors include EGF and
FGF or a combination thereof. Growth factors are usually
added to the culture medium at concentrations of between
about 1 fg/mL to 1 mg/mL. Concentrations between about 1
to 100 ng/mL are usually sufficient. Simple titration experiments routine in the art are used to determine the optimal
concentration of a particular growth factor for a particular cell
culture.
Cells of the invention that are proliferated in serum-free
media should be grown in the presence of a substituted deoxynucleotide or deoxynucleoside compound such as, for
example, halogenated-deoxynucleosides like bromodeoxyuridine (BrdU) or iododeoxyguanosine (IrdG), alkyl-substituted examples such as methyldeoxyguanosine, prior to transplantation into a host. The pre-transplant growth medium
comprises the components of the long-term propagation
media, but also contains substituted deoxynucleotide or
deoxynucleoside compound concentrations between about
10 nanomolar and 100 micromolar, more preferably between
about 2 and 50 micromolar, and more preferably about 10
micromolar. Pre-transplantation propagation can extend
between about 1 and 10' days, more preferably between about
1and5 days andmorepreferablybetweenabout 2 and3 days.
Specially adapted MNSCs prepared according to the methods
of the invention are conditioned or adapted to proliferate,
migrate and differentiate properly when transplanted into
host tissue such that, for example, a cognitive improvement
can be seen in an animal with a neurological deficit.
Cellular preparations and pharmaceutical compositions of
the MNSCs of the invention are also provided herein. Pharmaceutical compositions optimally comprise a therapeutically effective, amount of the MNSCs in admixture with a
pharmaceutically or physiologically, acceptable formulations
agent selected for suitability with the mode of administration.
Acceptable formulation materials preferably about nontoxic
to the specialty adapted MNSCs and th recipients at the dosages and concentrations employed.
The cellular preparations and pharmaceutical compositions of the invention may contain formulation materials for
modifying, maintaining, or preserving, for example, pH,
osmolarity, viscosity, clarity, color, isotonicity, odor, sterility,
stability, rate of dissolution or release, adsorption, or penetration of the composition, as well as proliferation, migration
and differentiation capacity of the specially adapted MNSCs
of the invention. Suitable formulation materials include, but
are not limited to, amino acids (such as glycine, glutamine,
asparagine, arginine, or lysine), antimicrobial compounds,
antioxidants (such as ascorbic acid, sodium sulfite, or sodium
hydrogen-sulfite), buffers (such as borate, bicarbonate, TrisHCl, citrates, phosphates, or other organic acids), bulking
agents (such as mannitol or glycine), chelating agents (such
as ethylenediamine tetraacetic acid (EDTA)), complexing
agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin, or hydroxypropyl-beta-cyclodextrin), fillers,
monosaccharides, disaccharides, and other carbohydrates

(such as glucose, mannose, or dextrins), proteins (such as
serum albumin, gelatin, or immunoglobulins), coloring, flavoring and diluting agents, emulsifying agents, hydrophilic
polymers (such as polyvinylpyrrolidone), low molecular
weight polypeptides, salt-forming counterions (such as
sodium), preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid, or
hydrogen peroxide), solvents (such as glycerin, propylene
glycol, or polyethylene glycol), sugar alcohols (such as mannitol or sorbitol), suspending agents, surfactants or wetting
agents (such as pluronics; PEG; sorbitan esters; polysorbates
such as polysorbate 20 or polysorbate 80; triton;
tromethamine; lecithin; cholesterol or tyloxapal), stability
enhancing agents (such as sucrose or sorbitol), tonicity
enhancing agents (such as alkali metal halides-preferably
sodium or potassium chloride--or mannitol sorbitol), delivery vehicles, diluents, excipients and/ or pharmaceutical adjuvants. See Remington's Pharmaceutical Sciences (18th Ed.,
A. R. Gennaro, ed., Mack Publishing Company 1990).
The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For
example, a suitable vehicle or carrier for injection may be
water, physiological saline solution, or artificial cerebrospinal fluid. Optimal pharmaceutical compositions will be determined by a skilled artisan depending upon, for example, the
intended route of administration, delivery format, desired
dosage and recipient tissue. See, e.g., Remington's Pharmaceutical Sciences, supra. Such compositions may influence
the physical state, stability, and effectiveness of the NSC
composition.
The invention provides methods of delivery and transplantation of the specially adapted MNSCs of the invention to
ameliorate the effects of age, physical and biological trauma
and degenerative disease on the brain or central nervous system of an animal, as well as other tissues such as, for example
retinal tissue. It is well recognized in the art that transplantation of tissue into the CNS offers the potential for treatment of
neurodegenerative disorders and CNS damage due to injury.
Transplantation of new cells into the damaged CNS has the
potential to repair damaged, circuitries and provide neurotransmitters thereby restoring neurological function. It is
also recognized in the art that transplantation into other tissue,
such as eye tissue, offers the potential for treatment of degenerative disorders and tissue damage due to injury. As disclosed herein, the invention provides methods, for generating
MNSCs adapted for proliferation, migraton and differentiation in mammalian tissue when introduced thereto. The use of
the MNSCs in the treatment of neurological disorders and
CNS damage, as well as the use ofNSCs in the treatment of
other tissue damage or degeneration, can be demonstrated by
the use of established animal models known in the art.
MNSCs of the invention can be administered to an animal
with abnormal or degenerative symptoms obtained in any
manner, including those obtained as a result of age, physical
or biological trauma, or neurodegenerative disease and the
like or animal models created by man using recombinant
genetic techniques, such as transgenic and "gene knockout"
animals.
Recipients of the MNSCs of the invention can be immunosuppressed, either through the use of immuno suppressive
drugs such as cyclosporin, or through local immunosuppression strategies employing locally applied immunosuppressants, but such immunosuppression need not necessarily be a
prerequisite in certain immunoprivileged tissues such as, for
example, brain and eye tissues. In certain embodiments, the
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delivery method of the invention can cause less localized
tissue damage to the site of cell damage or malfunction than
existing methods of delivery,
MNSCs of the invention can be prepared from the recipient's own tissue. In such instances, the progeny of the NSCs
can be generated from dissociated or isolated tissue and proliferated in vitro using the methods described herein. Upon
suitable expansion of cell numbers, the stem cells of the
invention can be harvested, treated according to the methods
of the invention and readied for administration into the recipient's affected tissue.
There are significant differences in the method of delivery
to the brain of the MNSCs of the invention as compared to the
prior art. One exemplary difference is as follows: the MNSCs
of the invention are transplanted intraventricularly. Further,
while the transplantation of one or more separate MNSCs is
efficacious, the MNSCs of the invention are preferably transplanted in the form of clusters of two or more cells via a
surgical procedure or injection using a syringe large enough
to leave the clusters substantially intact. The results disclosed
in the Examples below indicate that ventricular delivery of the
MNSCs of the invention in the form of a cluster of two or
more cells can result in migration to the area of damage in the
brain and proper neuronal differentiation. Another benefit of
intraventricular injection is less tissue destruction, resulting
in less localized recruitment ofimmune cells by the host. This
is evidenced by the lack of ventricular distortion, tumor formation, and increased host astrocyte staining without any
immunosuppression.
The method of delivery of the MNSCs of the invention to
the brain can be essentially duplicated for other immunoprivileged tissue such as, for example, the eye. Delivery of one or
a plurality of separate or two or more MNSCs of the invention
in the form of a cluster via injection using a syringe large
enough to leave any cluster or two or more cells that is present
substantially intact can result in migration to the area of
damage in the eye and proper tissue-specific differentiation.
There are examples in the art of intra-tissue injection
(brain) of dissociated and partially differentiated NSCs (see,
e.g., Benninger et al., 2000, Brain Pathol. 10: 330-341;
Blakemore et al., 2000, Cell Transplant. 9: 289-294; Rosser et
al., 2000, Eur. J. Neurosci. 12: 2405-2413; Rubio et al., 2000,
Mal. Cell. Neurosci. 16: 1-13). Further, the dissociation of
NSC clusters is known to cause immediate senescence of
NSCs and increase the vulnerability ofNSCs in culture. See,
e.g., Svendsen et al., 1998, J. Neurosci. Methods 85: 141-152.
Some aspects of the instant invention preferentially employ
injection of clusters of two or more cells, but the specially
adapted cells of the invention appear to migrate and differentiate appropriately when transplanted in non-cluster from as
well. As provided by this invention, intraventricular transplantation provides an alternative route to the site-specific
injection disclosed in the prior art. Using intraventricular
transplantation, grafted cells can gain access to various structures by the flow ofCSF, and transplantation of more <levelopmentally potent cells of the invention in cluster form can
act to prevent premature differentiation at inappropriate anatomical sites in the brain and central nervous system. Regarding the eye, intraocular administration of clusters of two or
more cells, for example into the vitreous fluid, allows the
more developmentally potent cells of the invention to migrate
to the area of degeneration or injury and differentiate appropriately
Delivery ofMNSCs of the invention into other, non-immunoprivileged tissues can also be carried out, particularly when
the MNSCs are autologous to the recipient, including systemically (e.g., intravenously).

Functional integration of the graft into the host's neural
tissue can be assessed by examining the effectiveness of
grafts on restoring various functions, including but not limited to tests for endocrine, motor, cognitive and sensory functions. Useful motor tests include tests that quantitate rotational movement away from the degenerated side of the brain,
and tests that quantitate slowness of movement, balance,
coordination, akinesia or lack of movement, rigidity and
tremors. Cognitive tests include tests of the ability to perform
everyday tasks, as well as various memory tests, including
maze performance such as the Morris water maze performance. For example, using the cells and methods of the
invention, MNSCs injected into the ventricle of 24-monthold rats after in vitro expansion displayed extensive and positional incorporation into the aged host brain with improvement of cognitive score (FIG. 2), as assessed by the Morris
water maze after 4 weeks of the transplantation. Results of the
experiments disclosed herein indicate that the aged brain is
capable of providing the necessary environment for MNSCs
of the invention to retain their multipotent status and demonstrate the potential for neuroreplacement therapies in age
associated neurodegenerative disease.
Functional integration of the graft into the host's other
tissue can be assessed by examining the effectiveness of
grafts on restoring various functions specific to the injured or
degenerated tissue, for example improvement in sight for
transplantation of stem cells of the invention to the eye.
Regarding the eye, using the cells and methods of the invention, MNSCs of the invention injected into the vitreous cavity
of rat eyes after in vitro expansion displayed extensive and
positional incorporation into the host eye tissue (FIG. 3) 4
weeks post-transplantation. Results of the experiments disclosed herein indicate that the eye, as with the brain, is
capable of providing the necessary environment for the
MNSCs of the invention to differentiate in a tissue-specific
manner, and thus demonstrate the-potential for replacement
therapies in injury or degeneration-associated tissue damage.
Without being restricted to any particular theory for the
mechanism of action of the cells and methods of the invention, there are at least two explanations for the beneficial
effects of transplantation of MNSC of the invention to cognitive function of the, host brain as well as the beneficial
effects of these MNSCs in other tissues. One is replacement
or augmentation. Neural circuits can be replaced or augmented by the MNSC-derived neurons. In other tissues, cells
and cell structures can also be replaced or augmented by
MNSC-derived cells appropriate for that tissue. An alternative explanation is the trophic action of factors released from
the transplanted MNSCs. Morphological analysis of rat
brains transplanted with the MNSCs as disclosed herein
showed extensive incorporation of the MNSCs and massive
growth of neural fibers in the host brain area related to spatial
memory task (FIGS. 3 and 4); however, the MNSCs may still
migrate toward the damaged neurons and rescue them by the
production of neurotrophic factors. Synergy between these
two explanations may also exist.
As assessed by the Morris water maze test, improvement in
spatial memory of animals transplanted with the specially
adapted MNSCs was accompanied by incorporation of the
MNSCs into the brain areas known to be related to spatial
memory. The post-transplant morphology of rat brain tissue
indicates that functional association of the transplanted cells
to the host brain occurs. Immunohistochemical analysis
revealed that the bIII-tubulin-positive donor-derived cells
found in the cerebral cortex are characterized by possessing
dendrites pointing to the edge of the cortex; whereas, in the
hippocampus, donor-derived neurons exhibited morpholo-
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gies with multiple processes and branches. These differential
morphologies of the transplanted MNSCs in different brain
regions indicate that site-specific differentiation of the
MNSCs occurs according to various factors present in each
brain region.
Strong astrocyte staining was also found in the frontal
cortex layer 3 and CA2 region of hippocampus in transplanted rat brains, areas where astrocytes are not normally
present in the animal. The migration of the MNSCs of the
invention to the CA2 is of particular interest because CA2
pyramidal neurons highly express bFGF, and the expression
of bFGF is up-regulated by entorhinal cortex lesions (see,
e.g., Eckenstein et al., 1994, Biochem. Pharmacol. 47: 103110; Gonzalez et al., 1995, Brain Res. 701: 201-226; Williams et al., 1996, J. Comp. Neural. 370. 147-158). CA2 pyramidal neurons in the host brain can express bFGF as a
response to a reduction of synaptic transmission, an event that
can occur during aging. Subsequently, this expressed bFGF
can act as a signal for the transplanted MNSCs to respond,
migrate or proliferate under the influence ofbFGF produced
in the host brain after the transplantation.
The regions rich in astrocyte staining transplanted rat
brains are the same regions where extensively stained neural
fibers were identified (FIGS. 3a, 3d and 3e). During development, glial cells have many complex functions, such as neural
and axonal guidance and production of trophic factors (see,
e.g. Pundt et al., 1995, Brain Res. 695: 25-36). This overlapping distribution of glial and neural fibers strongly suggests
that this interaction plays a pivotal role in the survival, migration, and differentiation of transplanted MNSCs.
Immunohistochemistry of transplanted rat brains reveals a
symmetrical distribution of neurons and astrocytes at both
sides of the host brain, indicating that the progeny of these
specially adapted MNSCs can migrate. Although astrocytes
have been shown to migrate over long distances following
transplantation (see, e.g., Blakemore et al., 1991, Trends Neurosci. 14: 323-327; Hatton et al., 1992, Glia 5: 251-258;
Lundberg et al., 1996, Exp. Neural. 139: 39-53), there is
experimental evidence showing that neurons do not migrate
as widely as glial cells (see, e.g., Fricker et al., 1999, J.
Neurosci. 19: 5990-6005). As disclosed herein, neural precursors derived from the MNSCs of the invention possess
similar migratory capacity to astrocyte precursors.
Information pertaining to neural stem cells is presented,
followed by information pertaining to retinal stem cells. One
of skill in the art will readily recognize the methods of the
invention are not limited to these three types of stem cells and
instead extend to cover all cell types not yet terminally differentiated.

origin in a biological process, for example, stroke, aneurysm,
epilepsy, brain tumor, hypoxia and the like.
Another source of impaired or improper brain function is
neurodegenerative disease. In recent years neurodegenerative
disease has become an important concern due to an expanding
elderly population that is at greatest risk for these disorders.
Neurodegenerative diseases include, but are not limited
Alzheimer's disease, amyotrophic lateral sclerosis (ALS),
Parkinson's disease, Pick's disease, Huntington's disease,
progressive supranuclear palsy, corticobasal degeneration,
Parkinson-ALS-dementia complex, Gerstmann-StrausslerScheinker syndrome, Hallervorden-Spatz disease, Kufs' disease, Wilson's disease, multiple sclerosis (MS), late-onset
metachromatic leukodystrophy and adrenoleukodystrophy.
The effects of these diseases can be counteracted by: administration of the MNSCs of the invention.
There is a variety of organic brain diseases that impairs
motor or cognitive function. Degeneration in the basal ganglia can lead to diseases with cognitive and motor symptoms,
depending on the exact location of the degeneration. Motor
deficits are a common result of degeneration in the basal
ganglia. Huntington's Chorea is associated with the degeneration of neurons in the striatum, which leads to involuntary
jerking movements in the host. Degeneration of a small
region called the subthalamic nucleus is associated with violent flinging movements of the extremities in a condition
called ballismus, while degeneration in the putamen and globus pallidus is associated with a condition of slow writhing
movements or athetosis. In Parkinson's disease, degeneration
is seen in another area of the basal ganglia, the substantia
nigra par compacta. This area normally sends dopaminergic
connections to the dorsal striatum, which are important in
regulating movement. Therapy for Parkinson's disease has
centered upon restoring dopaminergic activity to this circuit,
which can be accomplished by transplantation of neural stem
cells to this region of the brain according to the instant inventi on.
In Alzheimer's disease, another neurodegenerative disease, there is substantial cellular degeneration of the forebrain
and cerebral cortex. Further, a localized area of the basal
ganglia, the nucleus basalis of Meynert, appears to be selectively degenerated. This nucleus normally sends cholinergic
projections to, the cerebral cortex, which are thought to participate in cognitive functions including memory.
Although adult stem cells continue to possess some multipotency, cell types produced from adult stem cells are limited
by their tissue-specific character. For example, human NSCs
spontaneously differentiate into brain cells under basal media
conditions, but retinal or mesenchymal stem cells cannot
spontaneously differentiate into neural cells without the addition of certain factors (see concurrent application entitled
"Novel Mammalian Multipotent Stem Cells And Compositions, Methods Of Preparation And Methods Of Administration Thereof'). These results indicate that each stem cell
contains specific information that permits it to become a
special type of cell, i.e., they are partially committed to
become a particular type of cell in a tissue-specific manner. To
overcome this barrier of stem cell lineage, alterations to the
cells and their environment are necessary. However, the exact
regulation mechanisms of tissue-specific stem cell fate decisions remain unclear. This gap in the knowledge base poses an
important problem, because although NSCs can be isolated
and proliferated in culture, they cannot naturally differentiate
into non-neural-lineage cells. Further, untreated, unaltered
NSCs have not, hitherto, been known to migrate and differentiate properly such that a neurological or corporal deficit
could be remedied as shown in Example 1 below.
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Neural-Related
Due to the generally low proliferation rate of marmnalian
NSCs there is a correlation between advancing age and
impaired brain function even in the absence of specific neurodegenerative disease or physical or biological brain trauma.
The invention provides methods for counteracting impaired
brain function due to advancing age through the addition of
specially adapted MNSCs capable of proliferation, migration
and differentiation in mammalian brain when introduced
thereto.
Physical trauma and biological trauma are additional
causes of impaired or improper brain function. The term
"physical trauma" denotes brain cell damage due to external
sources such as blunt head trauma, severe concussion and the
like. Such physical trauma can be localized or general
depending on the source and severity of the trauma. The term
"biological trauma" denotes any acute brain injury that has its
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Retinal Related
Retinal degenerative diseases, including macular degeneration, are major causes of blindness. Despite investigations
into gene therapy, growth/survival factor injections and vitamin treatments, no effective vision-restoring treatments are
currently available. Visual impairment caused by the degeneration of photoreceptors or neural cells has been considered
incurable because of a long-held "truism"; neurons do not
regenerate during adulthood. However, this statement has
been challenged and we have found new evidence that these
cells do indeed have the potential to be renewed after maturation, thus opening a door for the development of novel
therapies to treat visual impairment by retinal regeneration B
using stem cell transplantation.
The capacity for retinal regeneration in cold-blooded vertebrates has long been recognized. Fish and amphibians continue to make new retinal neurons through a population of
retinal stem cells residing at the peripheral margin of the
retina, the so-called "ciliary marginal zone." Recent studies
have provided evidence that birds and adult mammals also
possess a zone of cells at the retinal margin analogous to the
ciliary marginal zone of cold-blooded vertebrates. These retinal stem cells are reported not only to generate photoreceptor
and other retinal cells in vitro, but also to differentiate into
retinal cells following transplantation into the retinal area.
Although these results indicate the possibility of retinal
regeneration therapy, since the number of retinal stem cells is
limited, we must locate an alternative source of stem cells for
use in clinical applications.
Neural stem cells have been isolated from embryonic and
adult mammalian brains and have been propagated in vitro in
a variety of culture systems. Using a serum-free unsupplemented media condition, NSCs spontaneously differentiated
into bIII-tubulin-, glial fibrillary acidic protein (GFAP)-, and
04-immunopositive cells, markers for neurons, astrocytes,
and oligodendrocytes, respectively. As described in the
examples below, NSCs treated according to methods of the
invention migrate and differentiate into neurons and glia after
transplantation into the brains of 24-month-old rats and significantly improved the cognitive functions of these animals.
This result led us to consider that MNSCs of the invention
could represent transplantable material to produce a retinal
stem cell alternative.
There are variety of factors involved in the development of
retinal tissue that regulate the proliferation and differentiation
of retinal cells. Transforming growth factor beta 3 (TGF-b3)
is thought to regulate cell proliferation during development
and influence the commitment or the differentiation, or both,
of neural progenitor cells to retinal fates. Treatment of embryonic day-18 rat retinal cultures with TGF-b-like protein
activin A, causes the progenitor cells in these cultures to exit
the cell cycle and differentiate into rod photoreceptors, indicating that the TGF family is an important regulator of photoreceptor differentiation in the developing retina. Treatment
of neural stem cells or MNSCs prepared according to the
invention before or concurrently with TGF-b3, CNTF, IGF-1,
or combinations of two or more thereof, can induce their
adoption of a retinal differentiation path in vitro. Further,
treatment of untreated neural stem cells or MNSCs of the
invention with one or more of the factors before or concurrent
with transplantation can induce their adoption of a retinal
differentiation path in vivo. "Retinal differentiation" and
"retinal cell" as used herein, refers to the various cell types
found in eye tissue, inter alia, chorid, Buchs and retinal pigment epithelium cells, rod and cone photoreceptor cells, horizontal cells, bipolar neurons, amacrine, ganglion and optic

nerve cells. These non-limiting, exemplary cell types found in
eye tissue are collectively referred to as retinal cells.
Previous transplantation studies ofNSCs into retinal tissue
with rd mice (a model of retinitis pigmentosa); mechanical
lesions, transient ischemia and normal retina have revealed
that donor cells migrate into the retinal area and differentiate
into neurons and glia, but they do not show any retinal cell
markers. These results indicate that NSCs are already committed to become neural tissue, and that this commitment is
not mutable solely by transplantation into the retina. Thus, to
differentiate NSCs into retinal cells, alteration of their epigenetic information before retinal transplantation appears necessary, something accomplished by the methods of the invention. Thus, using the methods of the invention, MNSCs can be
used as alternatives to retinal stem cells to repair ocular tissue
damage or promote tissue regeneration.
The inventive methods use BrdU and other substituted
deoxynucleotide or deoxynucleoside compounds to change
the cell fate decisions of NSCs to those of the specially
adapted MNSCs described herein. Such an invention is
important in the neuroreplacement therapy field because it
demonstrates cognitive improvement due to transplantation
of substituted deoxynucleotide or deoxynucleoside compound-treated NSCs. Stem cell can be purchased or isolated
from the patient, expanded in vitro, genetically modified and
transplanted back to the same patient. Since neural stem cells
of the invention can be differentiated to most peripheral tissue
cells, the invention is not only useful to neuroreplacement but
to other kinds of tissue regeneration or replacement as well. In
addition, in the case of autologous transplantation, there are
no ethical barriers or immunorejection issues with which to
contend.
There are a variety of neurological and corporal deficits
that can be addressed using the cells of the invention.
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Neurological Deficits" Amenable to Treatment
Because the invention relates to the discovery that multipotent neural precursor cells can be stimulated to divide and
migrate through the brain, it can be used to treat neurological
deficits caused by a wide variety of diseases, disorders, and
injuries. These insults include, but are not limited to, the
following (others of skill in the art may categorize differently
the diseases and disorders listed below; however categorized,
the neurological deficits with which they are associated are:
amenable to treatment according to the methods of the
present invention).
Degenerative Diseases
Degenerative diseases that can be treated according to the
methods of the invention include Alzheimer's disease (AD),
Parkinson's disease (PD), Huntington's disease (HD), Pick's
disease, progressive supranuclear palsy (PSP), striatonigral
degeneration, cortico-basal degeneration, childhood disintegrative disorder, olivopontocerebellar atrophy (OPCA;
including a heritable form), Leigh's disease, infantile necrotizing encephalomyelopathy, Hunter's disease, mucopolysaccharidosis, various leukodystrophies (such as
Krabbe's disease, Pelizaeus-Merzbacher disease, and the
like), amaurotic (familial) idiocy, Kufs disease, SpielmayerVogt disease, Tay Sachs disease, Batten disease, JanskyBielschowsky disease, Reye's disease, cerebral ataxia,
chronic alcoholism, beriberi, Hallervorden-Spatz syndrome,
and cerebellar degeneration.
Traumatic and Neurotoxic Injuries to the Central Nervous
System
Traumatic and neurotoxic injuries that can be treated
according to the methods of the invention include gunshot

US 7,618,621 B2

21

22

wounds, injuries caused by blunt force, injuries caused by
penetration injuries (e.g., stab wounds), injuries caused in the
course of a surgical procedure (e.g., to remove a tumor or
abscess from the CNS or to treat epilepsy), poisoning (e.g.,
with MPTP or carbon monoxide), shaken-baby syndrome,
adverse reactions to medication (including idiosyncratic
reactions), drug overdose (e.g., from amphetamines), and
post-traumatic encephalopathy.

treatable deficits include Creutzfeldt-Jacob disease and other
slow virus infectious diseases, AIDS encephalopathy, postencephalitic Parkinsonism, viral encephalitis, bacterial meningitis and meningitis caused by other organisms, phlebitis
and thrombophlebitis of intracranial venous sinuses, syphilitic Parkinsonism, and tuberculosis of the CNS.

Ischemia
Any disruption of blood flow or oxygen delivery to the
nervous system can injure or kill cells, including neurons and
glial cells, therein. These injuries can be treated according to
the methods of the present invention and include injuries
caused by a stroke (including a global stroke (as may result
from cardiac arrest, arrhythmia, or myocardial infarction) or
a focal stroke (as may result from a thrombus, embolus,
hemorrhage, or other arteral blockage)), anoxia, hypoxia,
partial drowning, myoclonus, severe smoke inhalation, dystonias (including heritable dystonias ), and acquired hydrocephalus.
Developmental Disorders
Developmental disorders that can be treated according to
the methods of the invention include schizophrema, certain
forms of severe mental retardation, cerebral palsy (whether
caused by infection, anoxia, premature birth, blood type
incompatbility: etc. and whether manifest as blindness, deafness, retardation, motor skill deficit, etc.), congenital hydrocephalus, metabolic disorders affecting the CNS, severe
autism, Down Syndrome, LHRH/hypothalamic disorder, and
spina bifida.
Disorders Affecting Vision
Disorders affecting vision, particularly those caused by the
loss or failure of retinal cells, can be treated according to the
methods and cells of the invention. These disorders include,
for example, diabetic retinopathy, serious retinal detachment,
retinal damage associated with glaucoma, traumatic injury to
the retina, retinal vascular occlusion, macular degeneration
(wet or dry), post-surgical healing, tumor, heritable retinal
dystrophies, optic nerve atrophy, and other retinal degenerative diseases. Cells targeted for repair utilizing cells and
methods of the invention include, for example, choroids,
Buchs, retinal pigment epithelial (RPE), rods, cones, horizontal cells, bipolar neurons, amacrine, ganglion, and optic
nerve.
Injuries and Diseases of the Spinal Cord
Injuries to or diseases affecting the spinal cord can also be
treated according to the methods of the invention. Such injuries or diseases include post-polio syndrome, amyotiophic
lateral sclerosis, nonspecified spinal degeneration, traumatic
injury (such as those caused by automobile or sporting accidents), including any injury that crushes, partially severs,
completely severs, or otherwise adversely affects the function
of cells in the spinal cord), injuries caused by surgery to the
spinal cord (e.g., to remove a tumor), anterior horn cell disease, and paralytic diseases.
Demyelinating or Autoimmune Disorders
Neurological deficits caused by demyelination or an
autoimmune response can be treated according to the methods of the invention. Such deficits can be caused by multiple
sclerosis, possibly lupus, and others.
Infectious or Inflannnatory Diseases
Neurological deficits caused by an infection or inflammatory disease can be treated according to the methods of the
invention. Infections or inflammatory diseases that can cause
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Miscellaneous
Those of ordinary skill in the art are well able to recognize
neurological deficits, regardless of their cause, and to apply
the methods of the present invention to treat patients who
have such deficits. In addition to the conditions listed above,
which are amenable to treatment with the methods described
herein, neurological deficits can be caused by Lesch-Nyhan
syndrome, myasthenia gravis, various dementias, numerous
parasitic diseases, epilepsy, and the like. Further, alleviation
of age-related memory loss is an object of the invention. The
methods of the invention can be readily applied to alleviate
neurological deficits caused by these and other diseases, disorders, or injuries.
"Corporal Deficits" Amenable to Treatment
The invention also relates to the amelioration of corporal
deficits utilizing multipotent precursor cells stimulated to
divide, migrate through damaged tissue and differentiate in a
tissue-specific manner. Cells according to the invention can
be used to treat corporal deficits caused by a wide variety of
diseases, disorders, and injuries, the result of which is trauma,
malfunction, degeneration or loss of muscle such as, for
example, cardiac muscle due to myocardial infarction. Other
examples include malfunction, degeneration or loss of other
cells and tissues apart from those discussed in the neurological deficit section above such as, for example, internal organs.
For example, liver function can be adversely affected by,
among other things, disease (e.g., cirrhosis or hepatitis),
trauma or age. Other exemplary internal organs amenable to
treatment utilizing the embodiments of the invention include
heart, pancreas, kidney, stomach, and lung. Corporal deficits
also comprise malfunction, degeneration or loss of skeletal
assets such as, for example, vertebrae.
An advantage of the cells of the invention is that they can be
genetically engineered according to routine procedures
knownintheart(See, e.g., Sambrook et al., 2001, MOLECULAR CLONING: A LABORATORY MANUAL. 3rd ed.,
Cold Spring Harbor Laboratory. Press: N.Y.). In certain
embodiments, constructs; encoding proteins of interest can
be provided to the cells. In other embodiments, constructs that
inhibit expression of desired proteins can be provided (such
as, for example, ribozymes and antisense molecules). In further embodiments, drug resistance genes and markers, or
detectable markers such as GFP can be provided. Preferably,
the marker and other genes are operably and genetically
linked to gene expression regulatory elements (including but
not limited to promoters and enhancers) that are operable in a
terminally differentiated cell derived from the MNSCs of the
invention or in the undifferentiated MNSCs of the invention
or both.
The following examples are presented in order to more
fully illustrate the preferred embodiments of the invention.
They should in no way be construed, however, as limiting the
scope of the invention, as defined by the appended claims.
EXAMPLES
Example 1

65

Improvement of Cognitive Function in Aged Rat by the
Transplantation ofMNSCs of the Invention
Human NSCs do not require any exogenous factors for
differentiation and survived: more than three weeks in basal
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media without the addition of any factor to support the survival (Qu et al. 2001, Neuroreport 12: 1127-32). Nevertheless, NSCs have heretofore not been successfully transplanted such that proper migration and differentiation and
cognitive improvement has been observed. Thus, it appears
that human NSCs produce factors to differentiate and support
themselves, which suggested that these cells could be transplanted into aged animals after treatment according to the
methods of the invention.
Human NSCs, expanded without differentiation under the
influence of mitogenic factors in supplemented serum-free
media and pre-treated by the incorporation of broniodeoxyuridine (BrdU) into the nuclear DNA, were injected into the
lateral ventricle of mature (6-month-old) and aged (24month-old rats. Human NSCs prepared according the methods of the invention survived 30 days after xenotransplantation into aged rat brain while retaining both multi potency and
migratory capacity, and also improved cognitive function in
24-month-old rats. Cognitive function of the animals was
assessed by the Morris water maze both before and four
weeks after the transplantation of human MNSCs of the
invention. Before human NSC transplantation, some aged
animals (aged memory unimpaired animals) cognitively
functioned in the range of mature animals, while others (aged
memory impaired animals) functioned entirely out of the
cognitive range of the mature animals. After transplantation
of the BrdU-treated human NSCs, most aged animals had
cognitive function in the range of the mature animals. Strikingly, one of the aged memory-impaired animals showed
dramatic improvement in its behavior, functioning even better
than the mature animals (FIG. 2a ). Statistical analysis showed
that cognitive function was significantly improved in both
mature and aged memory-impaired animals but not in aged
memory-unimpaired animals after BrdU-treated human NSC
transplantation (FIG. 2b ), which may be due to the physical
limitations of the aged animals. The performance of three of
the aged animals deteriorated in the water maze after transplantation of treated human NSCs. It is possible that the
physical strength of these animals deteriorated during the
experimental period.
These behavioral results indicate the beneficial effects of
the transplantation ofBrdU-treated human NSCs into the host
brain. After the second water maze task, postmortem brains
were further analyzed by immunohistochemistry for human
bIII-tubulinandhuman GFAP, markers for neurons andastrocytes respectively. There was no sign of ventricular distortion,
no evidence of tumor formation, and no strong host anti-graft
immunoreactivity was observed as revealed by weak host
Xastrocyte staining. Intensely and extensively stained with
bIII-tubulin, neurons with BrdU-positive nuclei were found
in bilateral singular and parietal cortexes (FIG. 3a-c) and
hippocampus (FIG. 3d,e). The bIII-tubulin-positive neurons
found in the cerebral cortex were typified by a dendrite pointing to the edge of the cortex. In the hippocampus, donorderived neurons exhibited multiple morphologies, varying in
cellular size and shape, and one or more processes and
branching.
Generally, GFAP-positive astrocytes were localized near
the area where neural cells were found. On further analysis
(overlapping images of their distributions), donor-derived
astrocytes were found to co-localize with neural fibers in the
cortex (FIG. 3j). These astrocytes were larger than the host
glia, with cell bodies 8-10 microns in diameter and thick
processes. Some of these astrocytes had a unilateral morphology (asymmetric), and the immunostaining formed a thin ring
around the nucleus, while the majority of the processes were
formed on the other side. Most cells appeared a symmetrical

with processes forming from all sides. The absence of this
type of cell in normal animal without the transplantation of
treated human NSCs was confirmed using immunohistochemistry for rat astrocytes host astrocytes had small cell
bodies with multiple delicate processes, and were distributed
throughout the brain mainly in white matter and around the
edges of the brain.
These results demonstrated that transplanted cells of the
invention migrated in rat brain and differentiated into appropriate cell types. The concomitant improvement in cognitive
function indicated that transplanted MNSCs of the invention
were functionally integrated into the recipient brains.
The following methods were used in this and several of the
following examples:
The Morris Water Maze: The Morris water maze consists
of a large circular tank (diameter, 183 cm; wall height, 58 cm),
filled with water (27° C.) and pacified by the addition of
powdered milk: (0.9 kg). Beneath the water surface (1 cm)
near the center of one of the four quadrants of a maze clear
escape platform (height, 34.5 cm) is positioned. The rats
receive three training trials per day for seven consecutive
days, using a 60 sec inter-trial interval. A training trial consists of placing the animal in the water for 90 seconds or until
the swimming rat successfully locates the platform. If the rat
fails to find the platform within the 90 seconds, the animal is
gently guided to the platform. For spatial learning assessment, the platform's location remains constant in one quadrant of the maze, but the starting position for each trial is
varied. Every sixth trial is a probe trial, during which the
platform is retracted to the bottom of the pool for 30 sec and
then raised and made available for escape. The training trials
assess the acquisition and day-to-day retention of the spatial
task while the probe tests are used to: assess search strategy.
At the completion of a spatial learning assessment, one session: with six trials of cue training is performed. Rats are
trained to escape to a visible black platform that is raised 2 cm
above the surface of the water. The location of the platform is
varied from trial to trial to assess sensor motor and motivational functioning independent of spatial learning ability.
Each rat is given 30 seconds to reach the platform and is
allowed to remain there briefly before the 30 second inter-trial
interval. Accuracy of performance is assessed using a learning index score computed from the probe trials. The learning
index is a derived measure from average proximity (cumulative search error divided by the length of the probe trial) on the
second, third, and fourth interpolated probe trials. Scores
from these trials are weighted and summed to provide an
overall measure of spatial learning ability. Lower scores on
the index indicate a more accurate search near the target
location; higher scores indicate a more random search and
poor learning.
Cell migration and differentiation: In order to investigate
differentiation and/or migration of cells of the invention in the
brain, MNSCs were transplanted into rodent brain. The animals were anesthetized with 50 mg/kgpentobarbital (i.p.) and
mounted in a stereotaxic apparatus (David Kopf). Approximately lxl04 to lxl0 5 cells in 5 µl phosphate-buffered saline
were injected into the ventricle using a micro syringe attached
to the stereotaxic apparatus. After removing the hair from the
surgical site using electric razor, an iodine swab was be
applied to the area and a 0.5 cm surgical incision was made
caudal to rostral in the skin at the surface of the cranium. The
ventricle was stereotaxically localized using the following
exemplary coordinates: AP=-0.58 mm from bregma, ML=+ 1
mm, and 2.4 mm below dura (for mouse): AP=-1.4 mm from
bregma, ML=+3.3 mm, and 4.5 mm below dura (for rat). A
0.4-mm hole was made in the cranium by careful drilling. The
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cells of the invention were injected into the ventricle using a
microsyringe. The injection was delivered over a period of
five minutes and the needle was left in place for an additional
two minutes following the injection. After the injection, the:
surgically incised skin was closed by Michel suture clip (2.5x
1.75 mm). Ten days post-surgery, proper healing of the incision site was observed, and the Michel sutures were removed.
The existence and location of the cells of the invention after
administration in rat brain were analyzed as follows. At 30
days post-transplantation, the rats were sacrificed by an overdose of sodium pentobarbital (70 mg/kg, i.p.) and perfused
with phosphate buffered saline (PBS) followed by 4%
paraformaldehyde. Brains were removed and incubated overnight in 4% paraformaldehyde fixative containing 20%
sucrose. The brains were sliced into 20 micron coronal sections using a cryomicrotome. The sections were washed
briefly in PBS and pretreated with IM HCl for 30 minutes at
room temperature and neutralized with sodium borate (0.1 M,
pH 8.0) for 30 minutes in order to increase the accessibility of
an anti-BrdU antibody to BrdU incorporated in the cell
nuclei. After rinsing with PBS, sections were transferred to a
solution containing 0.25% Triton X-100 in PBS (PBST) for
30 minutes. The sections were then blocked by incubation in
PBST containing 3% donkey normal serum for 1 hour, followed by incubating the sections overnight at 48° C. with
sheep anti-BrdU ( 1: 1000; Jackson IR Laboratories, Inc. West
Grove, Pa.) or mouse ariti-BrdU (1:200; DSHB, Iowa City,
Iowa) diluted in PBST. After rinsing the sections in PBS,
donkey anti-mouse or donkey anti-sheep conjugated to
rhodamine IgG (Jackson IR Laboratories, Inc.) was added at
a 1:200 dilution in PBST and the sections further incubated
for 2 hours at room temperature in the dark.
The transplanted cells of the invention, with BrdU:immunopositive nuclei, were stained for human bIII-tubulin and
human glial filament protein (GFAP). The sections were then
washed with PBS and incubated with mouse IgG2b monoclonal anti-human bIII-tubulin, clone SDL3D10 (1:500,
Sigma), goat antihuman. GFAP, N-terminal human affinity
purified;: (1:200, Research Diagnostics Inc., Flander, N.J.) or
mouse IgGl monoclonal anti-GFAP, clone G-A-5 (1:500,
Sigma), respectively, overnight at 48° C. in the dark. After
brief washing with PBS to remove excess primary antibody,
the location of primary antibody binding was then determined
using FITC-conjugated (Jackson IR Laboratories, Inc.) secondary: antibody (donkey anti-mouse (1 :200) or donkey antigoat IgG (H+L; 1:200), respectively) by incubating the sections for 2 hours at room temperature in the dark.
The sections were then washed with PBS thoroughly
before mounting to glass slides. The mounted sections were
covered with Vectashield using 4',6-diamidine-2phenylindole•2HC1 (DAPI, Vector Laboratories, Inc., Burlingame, Calif.) for fluorescent microscopic observation. Microscopic images were taken by using anAxiocam digital camera
mounted on the Axioscope 2 with Axiovision software
(Zeiss).
The transplanted NSCs, with BrdU immunopositive
nuclei, were stained for human bIII-tubulin and human GFAP.
Double immunolabeling with bIII-tubulin and BrdU in three
different planes from the same microscopic view clearly
showed the co-localization of these two signals in the same
cells (FIG. 4). According to the manufacturer's description,
the anti-bIII-tubulin antibody may also recognize the host
(rat) bIII-tubulin. Despite this, the specific co-localization of
the bIII-tubulin and BrdU at different planes indicate that the
majority of bIII-tubulin immunopositive cells were indeed
transplanted cells of the invention. This may be because bIIItubulin is mainly expressed in immature neurons, the major-

ity of which are transplanted cells as disclosed herein. The
presence of these cell specific antigens indicates that the
transplanted cells of the invention successfully differentiated
into neurons and astrocytes, respectively.
NSC culture: NSCs were purchased (Bio Whittaker, Walkersville, Md.), and alternatively isolated from human tissue,
and cultured in a nonsupplemented, serum-free basal medium
comprising HAMS-F12 (Gibco, BRL, Burlington, ON); antibiotic-antimycotic mixture (1:100, Gibco ); B27 (1:50,
Gibco ); human recombinant FGF-2 and EGF (20 ng/ml each,
Rand D Systems Minneapolis, Minn.) and heparin ( 5 ug/ml,
Sigma, St. Louis, Mo.). The cells were incubated at about 37°
C. in a 5% C0 2 humidified incubation chamber (Fisher, Pittsburgh, Pa.). To facilitate optimal growth conditions, NSC
spheroids were sectioned into' quarters every 2 weeks and fed
by replacing 50% of the medium every 4-5 days. To inhibit
differentiation, the cells can be propagated-on uncoated flask
or a flask that has been treated torepel the cells. To induce
differentiation, these cells can be replated in the culture
dishes (about lxl0 5 per dish) in the serum-free basal medium
Eagle (BME), which comprises Earle's salt and L-glutamine,
and cultured for about 5 days in the absence of FGF-2 and
EGF and without the addition of other extrinsic differentiation factors. NSCs cultured in this serum-free medium can
spontaneously undergo differentiation into neural cell types.
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In Vitro Propagation and Differentiation ofNSCs
Neural stem cells have been isolated from embryonic and
adult manimalian and human (Doetsch et al., 1999, Cell 97:
703-16; Johansson et al., 1999, Cell 96: 25-34) centralnervous system (CNS) and propagated in vitro in a variety of
culture systems (Svendsen et al., 1999, Brain Pathol. 9: 499513). The inability to grow neural progenitors in culture in the
absence of complex and undefined biological fluids (for
example, serum) has long been a major obstacle in understanding the physiology of these cells. Long-term culture
systems to proliferate NSCs were established (Brannon et al.,
2000, Neuroreport 11: 1123-8). The ability of multipotent
human NSCs to expand in vitro produces well-characterized
material for biological research. As grown in ling term culture, NSCs are differentiated into bIII-tubulin- and glial fibrillary acidic protein (GAFP)-immunopositive cells: (Brannon
et al., 2000, Neuroreport 11: 1123-8). After three years of in
vitro expansion, such human NSCs remain capable of producing neurons and glia on differentiation (FIG. 5) under
non-serum basal media conditions, indicating the multipotency of these cells, thus demonstrating that this culture system is optimal to maintain NSCs and to investigate their
biology.
Using the growth conditions disclosed herein, clusters of
two or more cells can form, from which coronary migrating
immature and/or mature neurons and astrocytes can derive
(FIG. 6).
Example 3

60

Retinal Differentiation ofNSCs with TGF-b3
Treatment In Vitro

65

Several studies have found that NSCs migrate into retinal
tissue after transplantation into the eye, but none of these
investigators has been able to detect op sin expression in these
cells (Nishida et al., 2000, Invest Ophthalmol Vis Sci 41:
4268-74; Kurimoto et al., 2001, Neurosci Lett. 306: 57-60;
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War:!Vinge et al., 2001, Exp. Neural. 169: p. 1-12), indicating
that NSCs do not spontaneously differentiate into photoreceptor cells. This observation was confirmed by immunostaining NSCs differentiated under basal condition without
any additional factors, which did not demonstrate opsin
expression. Thus, NSC cell fates were modified by epigenetic
means using factors known to modify the proliferation or the
differentiation of retinal progenitors during development.
Previously, opsin-positive cells were produced from NSCs in
vitro or in vivo through exposure ofTGF-b3.
Two kinds of differentiation studies were performed: treatment of human NSCs with factors (i) before and (ii) during
spontaneous differentiation under a basal media condition. In
the first example, NSCs were differentiated under a serumfree differentiation condition in the presence of TGF-b3
(R&D, 50 ng/ml (1 ng/ml to 1 ug/ml)) and VEGF (R&D, 50
ng/ml (1 ng/ml to 1 ug/ml)) for 5 days in Lab-Teck II chamber
slides (Nalge Nurre). The second example elucidated whether
pretreatment ofNSCs is sufficient to produce retinal lineages
in these cells. The NSCs were treated with these factors for 3
days, and then differentiated for 5 days under the serum-free
differentiation condition in the absence of these factors in the
Lab-Teck II chamber slides. As a control, human NSCs were
differentiated for 5 days in a no-factor treatment under a
serum-free differentiation condition. After differentiation,
cells were examined by double-immunofluorescent-cytochemistry (Kim eta!., 2002, Proc. Natl.Acad. Sci. USA99:
4020-5) with antibodies in a combination of goat anti-GFAP
(1:100, Research Diagnostics) and mouse anti-B-tubulin
(1:700, Sigma) or mouse anti-opsin (1:200, Chemicon).
NSCs could be differentiated into opsin-positive cells in vitro
by treating these cells with human recombinant TGF-b3 not
only before but also during spontaneous differentiation (FIG.
7c,d). No opsin-positive cells were detected in the spontaneous differentiation without TGF-b3 (FIG. 7b), the treated
cells were positive for bIII-tubulin and GFAP (FIG. 7a).
These results indicated that TGF-b3 treatment is necessary to
induce photoreceptor lineage in NSCs. Furthermore, the fact
that pretreatment with TGF-b3 was sufficient to transform
NSC lineages into retinal cell lineages suggested that trans
plantation ofNSCs into the rodent vitreous cavity could result
in differentiation of these cells into retinal tissue. Despite
successful differentiation ofNSCs treated with TGF-b3 into
opsin-positive cells in vitrolin vivo, no opsin-positive cells
were detectable by VEGF treatment (data not shown). Thus,
TGF-b3 and VEGF treatment were not sufficient to confer
retinal cell-differentiation to MeSCs, cells that are less developmentally potent with respect to NSCs (i.e., the MeSCs can
readily differentiate into a narrower group of tissue specialized cells), hence requiring the action of BrdU pre-treatment
to elicit retinal cell differentiation.

the right eye. The left eye was left intact as a control without
injection. At 30 days post-transplantation, the rats were sacrificed and their eyeballs were removed whole. Then these
eyeballs were paraffin embedded and sliced into 5 µm sections. The sections were stained with double-immunofluorescent-cytochemistry using rat anti BrdU (1 :600, Accurate
Chemical & Scientific Corp.) and mouse anti-rhodopsin
(1 :200, Chemicon), and mounted on slides, then coverslipped
using VECTASIELD mounting medium (Vector) with DAPI.
FIG. S(I) shows the immunocytochemistry and in situ
hybridization histochemistry (ISHH) of the hybridization histochemistry (ISHH) of the retinal sections 4 weeks after
transplantation ofNSCs pretreated with BrdU and TGF-b3.
Extensive migration of these cells into the lesioned area of the
retina was found (FIG. S(I)b ), similar to other researchers,
who found migration and incorporation of neural stem cells
into the retina after intraocular (Nishida et al., 2000, Invest
Ophthalmol Vis Sci 41: 4268-74; Kurimoto eta!., 2001, Neurosci Let. 306: 57-60; War:!Vinge et al., 2001, Exp. Neural.
169: 1-12). However, for the first time is, demonstrated herein
that human stem cells incorporated into the photoreceptor
layer are in fact able to express op sin immunoreactivity (FIG.
S(I)c ), in contrast to previous studies that did not report such
findings (ibid). Since anti-opsin antibody that recognized
both human and rat opsin protein was used, it was not determined whether opsin is expressed by the donor (human stem
cells) or by the host (rat cells). To overcome this technical
problem, ISHH was conducted as described below against the
human rhodopsin gene-encoding region. The cloned human
rhodopsin gene sequence does not recognize any other species of opsin genes listed by Genbank: in particular, this
sequence does not show a significant similarity to any DNA
sequence found in rat genes (data not shown). Using the
human opsin gene sequence as a DIG-labeled RNA probe,
human opsin expression was detected in the retina following
human stem cells transplantation (FIG. S(I)d). These results
indicate that both NSCs pretreated with BrdU and TGF-b3
not only were incorporated into the rat retina, but they also
differentiated into photoreceptor cells. NSCs that were not
pre-treated with BrdU, according to the methods of the invention were not able to migrate and differentiate in a tissueappropriate manner in vivo. FIG. S(II) shows immunocytochemistry of retinal sections 8 days after transplantation to
the eye of NSCs pretreated with TGF-b3, IGF-1 or CNTF.
NSCs grown in basal media differentiated to opsin-expressing cells in vivo after exposure to IGF-1, TGF-b3 orCNTF for
four days. Cells were treated with 20 ng/ml ofIGF-1 (S(II).a),
100 ng/ml ofTGF-b3 (S(II).b ), or 10 ng/ml ofCNTF (S(II).c)
prior to transplantation into rat eye. Double immunofluorescence staining with GFAP (red), opsin (green), markers for
astrocytes and-retinal cells, respectively. The blue signal represents counter staining for nuclei by DAPI. The transplanted
NSCs can differentiate into retinal cells through the action of
the growth factors.
Construction of exemplary human-specific opsin riboprobe-vectors: A 360 bp fragment of a human-specific
rhodopsin gene sequence (from 6241 bp to 6601 bp of
U49742) was selected. The selected human rhodopsin gene
sequence does not have a significant level of homology with
other rhodopsin genes from other species. In particular, this
sequence does not show a significant similarity to any DNA
sequence found in the rat genome (data not shown). The
selected human-specific rhodopsin gene sequence was amplified from human genome DNA by PCR using a forward
primer(5'-TTCCCAATGAGGGTGAGATT-3'; SEQ ID NO:
1) and a reverse primer (5'-GGAATTTCCCACTCTTTGTT3'; SEQ ID NO: 2). PCR amplification was conducted in 50 µl
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Example 4
Migration and Differentiation NSC of the Invention After
Transplant into Rat Vitreous Cavity
For transplanting NSCs into the vitreous cavity of rats,
cells were cultured with the long-term maintenance media as
described above, containing TGF-b3 (1 ng/ml to 10 micrograms/ml; here 100 ng/ml) and about 2 µM 5-bromo-2'-deoxyuridine (BrdU) for 3 days in a 6-well tissue culture without
differentiations before injection.
An injury was intentionally made by a needle while these
cells were injected to facilitate the migration ofNSCs. After
an injury, 20 µl of cell suspension, containing about 1.5xl 0 to
2xl 0 cells, was slowly injected into the intravitreous space of
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volumes containing control human genomic DNA (100 ng,
Invitrogen), lxamplification buffer (Invitrogen), 40 nM of
each primer, dNTP Mix (250 µM, Invitrogen) and Taq DNA
Polymerase (2.5U, Invitrogen), under conditions of: 95° C.
(30 seconds), 52° C. (30 seconds), and 72° C. (60 seconds) for
30 cycles. The PCR-amplified fragment was ligated into a
TOPO TA cloning in vitro transcription vector (Invitrogen)
after gel purification on 2% agar gel. The plasmid was transformed into E. coli-competent cells (Strategene) and the
clone was confirmed by sequencing the insert.
In situ hybridization histochemistry for human opsin
mRNA in paraffin embedded sections: Digoxigenin-labeled
human opsin-specific riboprobes are made by in vitro transcription. Reactions (20 µl) were performed in a reaction
mixture containing 4 µl of 5xtranscription buffer (USB Corporation), 2 µl of lOxdigoxigenin RNA-labeling mix (0.2
µg/ml, Roche), 1 µl of template DNA (PCR reaction
described above, 100 ng/µl); 2 µl of T7 RNA polymerase
(5U/µl, USB), and 11 µl of molecular biology grade water.
After mixing with a pipette, the reaction mixture was incubated at room temperature for 2 hours. The pro be was purified
by ethanol precipitation and dissolved in 100 µl, molecular
biology-grade water. 10 µl ofthis probe solution was used to
make the hybridization mixture. Rat eye sections were deparaffinized with xylene (Fis her) for 5 minutes at room temperature, and rehydrated using a serial concentration of ethanol
(Fisher) and distilled water at room temperature. The sections
were then washed with 0.1 M phosphate-buffered saline
(PBS), pH 7.4, for 15 minutes at room temperature followed
by incubation with 10 ng/ml of proteinase K (Sigma) for 30
minutes at 37° C. The sections were washed twice in glycine
solution (0.75 g glycine/100 ml of0.1 M PB, pH 7.4) for 5
minutes at room temperature and treated with 13% triethanolamine solution (pH 8.0) containing 2.5% acetic anhydride
for 10 minutes at room temperature. The sections were then
prehybridized with hybridization buffer after 2 washes with
2xSSC (saline-sodium citrate buffer, Sigma, pH 7.0) for 15
minutes each at room temperature (RT). Hybridization buffer
consists of 50% formamide, lxDenhardt's solution, 10%
dextran sulfate (Invitrogen), 4xSSC, 0.25 mg/ml yeast tRNA,
and 0.3 mg/ml herring sperm DNA. Hybridization was done
in the hybridization buffer containing 10 µl of digoxygenin
riboprobe as described above for 18 hours at 60° C. After
hybridization, the sections were washed twice with 4xSSC
buffer, followed by a stringency wash with 50% formamide
and 2xSSC for 30 minutes at 60° C. The sections were washed
twice with RNase buffer (10 mM Tris, pH 8.0, 0.5 M NaCl, 1
mM EDTA) for 10 minutes at room temperature and then
incubated with RNase solution (50 ug/ml of RNase
(Promega) in RNase buffer) for 30 minutes at 37° C. The
sections were washed with serial concentration of SSC buffer
(2x, 0.5x, O.lx) twice for 20 minutes at 60° C., except that the
last wash was done at RT. After rinsing with PBS, the probe
was visualized by immunodetection of digoxygenin with a
primary antibody, sheep anti-digoxigenin (1:500, Roche),
and secondary antibody with fluorescein (FITC)-conjugated
AffiniPure donkey anti-sheep IgG (1 :200, Jackson Laboratories).
Image and data analysis: Digitally-captured images from
fluorescent microscopy of cultured cells can be analyzed by
NIH Image software (NIH) with Cell Scoring, Particle Analysis, and Cell Analysis macros. The number of cells showing
particular antibody markers in the areas of interest can be
counted. In addition, total, cell number can be counted by
DAPI nuclei counterstaining and each cell population will be
expressed as a percentage of the total cell number. The results

from each treatment condition can be analyzed by ANOVA
and followed by post-hoc (Fisher's Protected LCD) analysis.
Example 5
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Transplantation ofMNSCs of the Invention to Nucleus Basalis Magnocellularis (NBM) Lesion Rat Model
Stem cell transplantation strategies are advocated inAlzheimer' s disease (AD) neuroregeneration therapy: Basal cholinergic neurons, which are selectively degenerated in AD,
extend long projections into the cortex and hippocampus. An
open question for neuroreplacement treatment for AD is
whether these degenerating cholinergic cells can be replaced
by the transplantation of stem cells. To answer this question,
cells of the invention were transplanted into nucleus basalis
magnocellularis (NBM) lesion model rats. The lesions were
induced either by an injection ofibotenic acid or by anti-NGF
receptor antibody conjugated with saporin (Advanced Targeting System, San Diego, Calif.). Cells prepared according to
the invention were simultaneously injected into the contralateral side of the lateral ventricle (Qu, 2001) of the NBMlesioned animal. Four weeks after the surgery, the brain was
examined by immunohistochemistry. Many GFAP-positive
cells were detected in the lesioned area, but they were not
BrdU-positive, indicating astrocytes activation in this area.
BrdU-positive cells with ChAT or bIII-tubulin immunoreactivity were found in the lesion site, indicating that MNSCs of
the invention migrated from the contralateral ventricle to the
lesion site and had differentiated into cholinergic and other
neural cells. These neurally differentiating cells were neurons
that appeared rather morphologically premature. Our results
indicate a positive study of neuroreplacement treatment for
cholinergic neurons in, AD.
Transplantation of cells of the invention: Male SD rats
were deeply anesthetized with sodium pentobarbital (50
mg/kg, i.p.). Using bregma as a reference point, about lxl0 5
cells of the invention were collected and slowly injected into
the right lateral ventricle(AP 1.4; ML3.3; and DY 4.5mm)of
the rat brain using a stereotaxic apparatus (Devid Kopff).
Cholinergic lesions induced by 192-IgG-saporin conjugate: Male Sprague-Dawley rats, 4-months-old, are anesthetized with 50 mg/kg pentobarbital and mounted in a stereotaxic apparatus (David Kopf). Unilateral NBM injections of
the 1 µg/2 µ1192-IgG-saporin conjugate toxin (in a vehicle of
sterile filtered 200 mM phosphate buffer (pH 7.4)) were performed using a microsyringe. The NBM was stereotaxically
localized using the following coordinates: AP=-2.3 mm from
bregma, ML=±3.7 mm, 7.5 mm below dura. The toxin was
delivered over 5 minutes and the needle was left in place for
another 5 minutes following injection.
Immunohistochemistry: The rats were sacrificed by an
overdose of anesthesia (sodium pentobarbital, 70 mg/kg, i.p.)
and perfused with phosphate buffered saline (PBS) followed
by 4% paraformaldehyde. Brains were removed and placed
into the 4% paraformaldehyde fixative containing 20%
sucrose for overnight. The brains were sliced into 20 µm,
coronal sections using cryomicrotome. The sections were
washed briefly in PBS and pretreated with IM HCL for 30
minutes at room temperature (RT) and neutralized with
sodium borate (O.lM, pH 8.0) for 30 minutes, in order to
increase the accessibility of the anti-BrdU antibody to the
BrdU incorporated in the cell nuclei. After rinsing with PBS,
sections were transferred to a solution containing 0.25% Triton X-100 in PBS (PBST) for 30 minutes. Then the sections
were blocked in PBST containing 3% donkey normal serum
for 1 hr and incubated in mouse anti-BrdU (1 :200; DSHB,
Iowa City, Iowa) or sheep anti-BrdU (1: 1000; Jackson IR
Laboratories, Inc. West Grove, Pa.) diluted in PBST overnight at 4 degC. The sections were then washed with PBS and
incubated with mouse IgG2b monoclonal anti-human bIII-
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tubulin, clone SDL3D 10 (1: 500, Sigma), rat IgG monoclonal
anti-ChAT (1 :500, Boerhinger-Mannheim) and goat anti-human-glial filament protein, N-terminal human affinity purified(1:200, Research Diagnostics Inc., Flander, N.J.), respectively, for overnight at 4 degC in the dark. After rinsing in
PBS, donkey anti-mouse, donkey anti-rat, donkey anti-goat
or donkey anti-sheep IgG conjugated, with rhodamine or
FITC (Jackson IR Laboratories, Inc.) are added at 1:200
dilution in PBST for 2 hours at RT in the dark. Sections were
then washed with PBS thoroughly before mounting on glass
glides. The sections were coverslipped with mounting media
containing DAPI for nucleus counter staining.
Increased GFAP immunoreactivity in the NBM was
observed 4 weeks after saporin lesion. (FIG. 9. Green: GFAP;
Blue: DAPI). Choline acetyltransferase (ChAT) immunoreactivity was also observed in BrdU positive cells in the lesion
site (FIG. lOa-c. Green: ChAT; Red: BrdU; Blue: DAPI),
indicating replacement of lesioned cells by the transplanted
cells of the invention. Further, ChAT immunoreactivity was
observednhumannuclei positive cells in the lesion site. (FIG.
lOd. Green: ChAT; Red: human nuclei; Blue: DAPI). Human
nuclei immunoreactivity-positive cells were observed in the
lesion area (FIG. 11. Red: human nuclei; Blue: DAPI) and
GFAP and human nuclei immunoreactivity were observed in
the lesion site. (FIG. 12. Green: GFAP; Red: human nuclei;
Blue: DAPI). A large numberof transplanted cells migrated to
the lesion site and differentiated into rather mature neurons
and glia 4 weeks after transplantation. The lesion appears to
attract the cells of the invention, indicating a possible release
of the migration factor(s) from the lesion site.
It should be understood that the foregoing disclosure
emphasizes certain specific embodiments of the invention
and that all modifications or alternatives equivalent thereto
are within the spirit and scope of the invention as set forth in
the appended claims.

We claim:
1. One or a plurality of mammalianmultipotent neural stem
cells that can form a cluster produced according to the method
comprising the steps of:
a. isolating mammalian neural stem cells from mannnalian
neural tissue containing at least one neural stem cell,
b. culturing the neural stem cells in a cell culture media
under conditions that permit proliferation of the neural
stem cells in vitro, in the presence of substituted deoxynucleotide or deoxynucleoside in an amount effective to
adapt the cells to proliferate, migrate and differentiate
when transplanted into host tissue and at least one
growth factor, wherein cells are cultured in an uncoated
flask or a flask that has been treated to repel the cells, and
wherein the substituted deoxynucleotide or deoxynucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine,
or chlorodeoxyuridine, to generate the one or a plurality
of mannnalian multipotent neural stem cells that can
form a cluster, and
c. thereafter harvesting the one or plurality of mannnalian
multipotent neural stem cells that can form a cluster
produced in (b ).
2. A composition comprising, as an active ingredient, the
one or
a plurality of mammalian multi potent neural stem cells that
can form a cluster produced according to the method
comprising the steps of:
a. isolating mammalian neural stem cells from mannnalian
neural tissue containing at least one neural stem cell,
b. culturing the neural stem cells in a cell culture media
under conditions that permit proliferation of the neural
stem cells in vitro, in the presence of substituted deoxy-
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SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS, 2
<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>

SEQ ID NO 1
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, Forward primer
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1) .. (20)
OTHER INFORMATION, Forward primer

<400> SEQUENCE, 1
ttcccaatga gggtgagatt

<210>
<211>
<212>
<213>
<220>
<223>
<220>
<221>
<222>
<223>

20

SEQ ID NO 2
LENGTH, 20
TYPE, DNA
ORGANISM, Artificial
FEATURE,
OTHER INFORMATION, Reverse primer
FEATURE,
NAME/KEY, misc_feature
LOCATION, (1) .. (20)
OTHER INFORMATION, Reverse primer

<400> SEQUENCE, 2
ggaatttccc actctttgtt

20
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nucleotide or deoxynucleoside in an amount effective to
5. A method of preparing one or a plurality of manimalian
multipotent neural stem cells that can form a cluster comprisadapt the cells to proliferate, migrate and differentiate
ing the steps of:
when transplanted into host tissue and at least one
a. isolating mammalian neural stem cells from manimalian
growth factor, wherein cells are cultured in an uncoated
neural tissue containing at least one neural stem cell,
flask or a flask that has been treated to repel the cells, and
b. culturing the neural stem cells in a cell culture media
wherein the substituted deoxynucleotide or deoxyunder conditions that permit proliferation of the neural
nucleoside is bromodeoxyuridine, bromodeoxycytidine, bromodeoxyguanosine, methyldeoxythymidine,
stem cells in vitro, in the presence of substituted deoxyor chlorodeoxyuridine, to generate the one or a plurality
nucleotide or deoxynucleoside in an amount effective to
of mammalian multipotent neural stem cells that can 10
adapt the cells to proliferate, migrate and differentiate
form a cluster, and
when transplanted into host tissue and at least one
growth factor, wherein cells are cultured in an uncoated
c. thereafter harvesting the one or plurality of manimalian
flask or a flask that has been treated to repel the cells, and
multipotent neural stem cells that can form a cluster
wherein the substituted deoxynucleotide or deoxyproduced in (b ).
nucleoside is bromodeoxyuridine, bromodeoxycyti3. A pharmaceutical composition comprising, as an active 15
dine, bromdeoxyguanosine, methyldeoxythymidine, or
ingredient, one or a plurality of mammalian multi potent neuchlorodeoxyuridine, to generate the one or a plurality of
ral stem cells that can form a cluster produced according to
mammalian multipotent neural stem cells that can form
the method comprising the steps of:
a cluster, and
a. isolating mammalian neural stem cells from mammalian
c. thereafter harvesting the one or plurality of manimalian
20
neural tissue containing at least one neural stem cell,
multipotent neural stem cells that can form a cluster
b. culturing the neural stem cells in a cell culture media
produced in (b ).
under conditions that permit proliferation of the neural
6. The method of claim 5 wherein the growth factor in the
stem cells in vitro, in the presence of substituted deoxyculture media prepared in (b) is fibroblast growth factor,
nucleotide or deoxynucleoside in an amount effective to
adapt the cells to proliferate, migrate and differentiate 25 epidermal growth factor or combinations thereof.
7. The method of claim 6 wherein the growth factor is
when transplanted into host tissue and at least one
fibroblast growth factor or epidermal growth factor.
growth factor, wherein cells are cultured in an uncoated
8. The method of claim 6 wherein the growth factor is
flask or a flask that has been treated to repel the cells, and
fibroblast growth factor.
wherein the substituted deoxynucleotide or deoxy9. The method of claim 6 wherein the growth factor is
nucleoside is bromodeoxyuridine, bromodeoxycyti- 30
epidermal
growth factor.
dine, bromodeoxyguanosine, methyldeoxythymidine,
10. The method of claim 5 wherein the culture media of
or chlorodeoxyuridine, to generate the one or a plurality
step (b) further comprises heparin.
of mammalian multipotent neural stem cells that can
11. The method of claim 5 wherein said mammalian neural
form a cluster, and
c. thereafter harvesting the one or plurality of manimalian 35 tissue is obtained from an embryo, fetus, infant, juvenile, or
adult.
multipotent neural stem cells that can form a cluster
12. The method of claim 5 wherein said mammalian neural
produced in (b ).
tissue is obtained from a human.
4. The pharmaceutical composition according to claim 3
further comprising a pharmaceutically acceptable carrier.
* * * * *

